


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 213/81, 213/89, C07C 233/77, A61K 31/44	A1	(11) International Publication Number: WO 97/00245 (43) International Publication Date: 3 January 1997 (03.01.97)
(21) International Application Number: PCT/US95/07766 (22) International Filing Date: 14 June 1995 (14.06.95) (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; Suite 510, 2150 Shattuck Avenue, Berkeley, CA 94704 (US). (72) Inventors: RAYMOND, Kenneth; 99 Whitaker Avenue, Berkeley, CA 94708 (US). XU, Jide; Apartment A, 1704 Francisco Street, Berkeley, CA 94703 (US). (74) Agent: HEINES, M., Henry; Townsend and Townsend and Crew, Steuart Street Tower, One Market Plaza, San Francisco, CA 94105-1492 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, ARIPO patent (KE, MW, SD, SZ, UG), European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>


(54) Title: 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS



(2)



(3)



(4)

(57) Abstract

Disclosed is a series of improved metal chelating agents, selected from the group consisting of: (2), (3) or (4) which are highly effective upon both injection and oral administration; several of the most effective are of low toxicity. These chelating agents incorporate within their structure 1-hydroxy-2-pyridinone(1,2-HOPO) and 3-hydroxy-2-pyridinone(3,2-HOPO) moieties with a substituted carbamoyl group ortho to the hydroxy or oxo groups of the hydroxypyridinone ring. The electron-withdrawing carbamoyl group increases the acidity of the hydroxypyridinones. In the metal complexes of said chelating agents, the amide protons form very strong hydrogen bonds with its adjacent HOPO oxygen donor, making these complexes very stable at physiological conditions. The terminal N-substituents provide a certain degree of lipophilicity to said 3,2-HOPO, increasing oral activity. Also disclosed is a method of making the chelating agents and a method of producing a known compound, 3-hydroxy-1-alkyl-2(1H)-pyridinone, used as a precursor to the chelating agent, safely and in large quantities.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

1
2
3
4
5
6
7
8
9 TITLE OF INVENTION10
11 3-HYDROXY-2(1H)-PYRIDINONE CHELATING AGENTS
12
13
14
1516 STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY-
17 SPONSORED RESEARCH AND DEVELOPMENT
18

19 This application is a continuation-in-part of an earlier filed application entitled "1,4-
20 Disubstituted 3-Hydroxy-2(1H)-Pyridinone Chelating Agents," serial number 08/227,96, filed
21 04/13/94, herein incorporated by reference.

22 The Government has rights in this invention pursuant to Contract No. DE-AC03-
23 76SF00098 awarded by the U.S. Department of Energy. The uranium and plutonium
24 chemistry is supported through DOE. The iron chemistry is supported on the Berkeley
25 campus by NIH grants AI 11744 and DK 32999. The plutonium decorporation and ligand
26 toxicology are supported by NIEHS grant ES 02698.

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

The present invention relates generally to improved therapeutic metal chelating agents which are highly effective and have low toxicity upon injected and oral administration, and in particular to chelating agents which incorporate within their structures 1-hydroxy-2-pyridinone (1,2-HOPO) and 3-hydroxy-2-pyridinone (3,2-HOPO) moieties with a carbamoyl group substituted on the ring carbon atom ortho to the hydroxy or oxo group of the HOPO ring.


DESCRIPTION OF RELATED ART INCLUDING INFORMATION DISCLOSED

UNDER §§ 1.97-1.99


Siderophores are highly selective and effective ferric chelating agents synthesized and released by microorganisms to ensure the presence of sufficient iron in solubilized form for cell reproduction. It was recognized early on that the affinity and selectivity of the siderophores for ferric ion made these compounds good candidates for therapeutic iron removal agents. This is particularly true for patients who suffer from blood diseases such as beta thalassemia, the treatment of which requires the regular transfusion of whole blood and results in the accumulation of massive tissue iron deposits. Because of the similarity in coordination properties between Fe(III) and tetravalent actinides, tetravalent actinides have great affinity for electron-donor groups that bind Fe(III), and follow Fe(III) in mammalian iron transport and storage systems. The great affinity and specificity of the siderophores towards Fe(III) suggest that modification of siderophores, which are effective sequestering agents for ferric ion, would yield potential chelators of tetravalent actinides, which present significant biological hazards associated with nuclear technology. Following absorption, the actinide cations that have been inhaled, ingested, or deposited in a wound circulate in serum

1 bound to transferrin (Tf), the iron transport protein, and renal and gastrointestinal excretion
2 are severely inhibited. As actinide-containing cells and structures die, the released actinide
3 is recirculated, and nearly all of it is re-deposited at new sites. The alpha particles emitted
4 by the actinides kill cells and induce cancer in the major storage tissues--lung, bone, liver.
5 The only known way to reduce the toxicity of these radioactive metals is to use chelating
6 agents to accelerate their excretion, thereby preventing deposition or re-deposition.
7 Normally, such actinide chelating agents will be octadentate ligands, as opposed to the
8 generally hexadentate or tetradentate siderophores. Other uses, such as radionuclide
9 chelation in nuclear medicine applications, for example, are also clearly possible.

10 The biomimetic approach of the present invention, which designs and synthesizes
11 sequestering agents for ferric ion and actinides, are based on siderophores. The metal
12 binding units of siderophores are usually either catechols (dihydroxybenzene analogues;
13 Formula 1A) or hydroxamic acids (Formula 1B):



Formula 1A



Formula 1B

17 In fact, desferrioxamine B (DFO), a tri-hydroxamic acid siderophore, is used as a human
18 iron sequestering agent. This chelating agent has predominated for over 30 years as the
19 method of choice for treatment of iron overload. However, DFO has low oral activity and a
20 number of adverse effects: including administration via a cumbersome subcutaneous
21 infusion, leading to poor patient compliance with the treatment regime, and poor efficacy in
22 removing deposited actinides. As a result of these limitations of the prior art drugs, there is
23 a need for more effective and orally active iron sequestering agents to treat iron overload as
24 well as actinide poisoning.

1 The most potent natural Fe(III) chelator is enterobactin, a siderophore produced by
2 enteric bacteria with a formation constant of $K_f \approx 10^{49}$, $pM = 35.5$. This hexadentate ligand
3 is composed of three catechoylamide groups attached to a tri-serine lactone backbone.
4 Catecholates are much stronger sequestering agents than hydroxamate ligands, such as DFO,
5 and these ligands are faster in removing iron from human transferrin, primarily for kinetic
6 rather than thermodynamic reasons. Synthetic analogues of catechol-based siderophores are
7 also known. However, there are a number of difficulties in developing catecholates into
8 effective pharmaceutical agents. A number of catecholate siderophores, including
9 enterobactin, will be bound by albumin in serum. They also strongly promote the growth of
10 pathogenic microorganisms. The weak acidity of catechol and the required loss of two
11 protons per catechol group at or about neutral pH limit the effectiveness of catechol-based
12 ligands *in vivo*. These factors place severe limitations on the use of catechol-based ligands
13 as therapeutic agents. It is therefore desirable to provide a medicinally useful metal
14 chelating agent having a higher K_a , i.e., more acidic, and which therefore binds more
15 effectively at physiological pH, than catechol-based compounds. Uninegative ligands, i.e.,
16 ligands having a single negative charge near neutral pH range, are particularly desirable, in
17 contrast to the correspondingly highly charged ferric and plutonium catechol complexes.

18 Derivatives of hydroxypyridinones ("HOPO") are of particular interest, since these
19 ligands selectively display high affinity for ferric and actinide ion. These ligands and their
20 mono-anions have a zwitteronic resonance form that is isoelectronic with the catechol
21 dianion. The abbreviation "HOPO" will hereinafter be used to include hydroxypyridinone
22 analogues as well as isomers or tautomers thereof, in either protonated or deprotonated
23 forms.

24 The HOPO ligands have been shown to be very promising sequestering agents. The
25 bidentate 3,4-HOPO ligand, 1,2-dimethyl-3-hydroxy-4-pyridinone, is orally active and has
26 gone through extensive study, including clinical trials. However, there are many limitations
27 for such a simple bidentate ligand. Multidentate HOPO derivatives have advantages over

1 simpler bidentate ligands: in particular, low toxicity resulting from a higher binding affinity
2 (pM) at low (clinical level) ligand concentrations.

3 Previous patents on hydroxypyridone ligands used as chelating agents include
4 "Hydroxypyridonate Chelating Agents", US Patent Number 4,698,431, patented by Kenneth
5 N. Raymond, Robert C. Scarrow, and David L. White, October 6, 1987. This invention
6 provided 1,2-HOPO derivatives with either an amide or a carboxylic acid moiety in the
7 number 6 position. These chelating agents are useful in selectively removing certain cations
8 from solution and are particularly useful as ferric ion and actinide chelators. However,
9 Patent Number 4,698,431, did not claim other chelating agents having 3,2-HOPO moieties
10 incorporated within their structures or a carboxy moiety on the number 3 position of 1,2-
11 HOPO ring.

12 Other related art includes Pharmaceutical Compositions of Hydroxypyridones, US
13 patent number 4,666,927, patented by Robert C. Hider, George Kontoghiorghes, Jack Silver,
14 and Michael A. Stockham, May 19, 1987. Claim 1 of this patent claims a number of
15 possible chelating agents having 1,2-HOPO, 3,2-HOPO, or 3,4-HOPO moieties
16 incorporated within their structures that are linked through a number of possible
17 combinations of linking groups, including -CONH- groups. However, US Patent Number
18 4,666,927 teaches against a HOPO moiety having a substitution ortho to the hydroxy or oxo
19 group of the HOPO ring.

20 In contrast to US patent number 4,666,927, the inventors have developed a new
21 design strategy, that is to synthesize a new series of 3,2-HOPO derivatives with either a
22 carboxylic acid or a (substituted) carbamoyl moiety substituted on the ring carbon ortho to
23 the HOPO hydroxy group. The particular coordination geometry and the hydrogen bonding
24 between the amide proton and HOPO oxygen donor in these HOPO-metal complexes
25 disclosed by the present invention thereby make the new series of 3,2-HOPO derivatives
26 unusually good complexing agents having very high stability and specificity towards metal
27 binding. The inventors further found these new compounds have stronger acidity and

1 chelating ability for iron and actinides and have high oral activity in removing toxic
2 actinides *in vivo*.

3 Furthermore, the method of synthesizing the present invention having 3,2-HOPO
4 moieties incorporated within their structures with the (substituted) carbamoyl group ortho to
5 hydroxy group of HOPO ring is not obvious. One earlier attempt by the inventors included:
6 reacting 4-carboxy-3-hydroxy-2(1H)-pyridinones (Formula 9A) with 1,1'-
7 carbonyldiimidazole to produce the active amide intermediate, which is then reacted with
8 backbone amines to form the corresponding novel 3,2-HOPO ligands, similar to the case of
9 thiohydroxamate. See, e.g., Kamal Abu-Dari and Kenneth N. Raymond, "Ferric Ion
10 Sequestering Agents. 23. Synthesis of Tris(hydroxypyridinethione) Ligands and Their
11 Ferric Complexes; X-ray Structure Analysis of N,N',N"-Tris(1,2-didehydro-1-hydroxy-2-
12 thioxopyrid-6-yl)carbonyl)-2,2',2"-triaminotriethylaminato)iron(III)," *Inorg. Chem.* 1991,
13 30, 519-524. However, the purification of the final product is difficult, therefore, this
14 method is not preferred. A second attempt to carry out the above reaction produced the acid
15 chloride of 1-alkyl-4-carboxy-3-hydroxy-2(1H)-pyridinone as an active intermediate using
16 thionyl chloride or oxalyl chloride, similar to the case of catechoylamide ligands. Due to
17 the low yield of compound in preliminary tests, this method is also not preferred.

18 The present invention discloses a process to synthesize the desired multidentate 1,2-
19 HOPO and 3,2-HOPO ligands in good yield.

20 Accordingly the present invention comprises an effective multidentate siderophore
21 analogue HOPO ligand in which one or more HOPO rings are linked to a molecular
22 backbone through amide linkage. The inventors have previously reported the synthesis of
23 siderophore analogues with linear, multipodal and macrocyclic topologies, and have shown
24 a more effective ligand is one with a greater predisposition toward binding. In the design of
25 the present invention, these synthetic strategies, as well as the binding abilities, solubility
26 and lipophilicity of the resulted compounds, are important factors considered.

27

SUMMARY OF THE INVENTION

The present invention represents a breakthrough in siderophore-like ligands intended for pharmaceutical use. The present invention provides novel 1,2-HOPO and 3,2-HOPO chelating agents capable of selectively forming stable complexes with certain cations such as Fe^{3+} , Gd^{3+} , Am^{3+} , Pu^{4+} , Np^{4+} , and U^{6+} ions.

The present invention allows this highly advantageous class of chemicals to be administered orally or by injection.

These complexing agents are lipophilic enough to display oral activity.

The present invention provides a method to produce these compounds safely and in good yield.

The present invention provides unusually good complexing agents with high stability and specificity for iron and actinides.

The present invention provides chelating agents which are relatively acidic and incorporate monoprotic ligand groups.


The present invention provides methods of using the novel chelating agents.

The present invention provides methods of synthesizing the novel chelating agents. These new HOPO ligands are generally synthesized by introducing a carboxylate group at the carbon atom ortho to the ligating group of HOPO ring, then making an amide linkage to a suitable molecular backbone.


In one aspect of the invention, novel chelating agents are provided which include HOPO-based bidentate and multidentate ligands, as well as mixed multidentate ligands such as HOPO-substituted desferrioxamine. In other aspects of the invention, novel methods of synthesizing the HOPO-derived chelating agents are provided, as are methods of using the novel compounds.

DETAILED DESCRIPTION OF THE INVENTION


The present invention provides novel 1,2-HOPO and 3,2-HOPO chelating agents capable of selectively forming stable complexes with certain cations such as Fe^{3+} , Gd^{3+} , Am^{3+} and Pu^{4+} , Np^{4+} , and U^{6+} ions. Accordingly the present invention comprises a compound consisting of 4-(substituted)carbamoyl-3-hydroxy-2-pyridinones having optional substituents on the nitrogen atom, and on one or more of the carbon atoms of the ring. Shown below are the preferred basic ring system in the compounds of the present invention (Formula 2), the basic ring system of 1,2-HOPO-6-carbamoylamide (Formula 3), and catechoylamide (Formula 4):



Formula 2




Formula 3



Formula 4


wherein R_1 and R_2 are separately selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group.

The HOPO rings are attached to a molecular or polymeric backbone R through amide linkages, where R is selected from multi-linking groups. Representative examples of such multi-linking groups include, but are not limited to:



Formula 5A

(m = 1-3, n = 1-3, p = 1-3)




Formula 5B

(m = 1-3, n = 1-3, p = 1-3)




Formula 5C

(m = 1-6)




Formula 5D

(R'' = H, alkyl)




Formula 5E

(m = 1,2)




Formula 5F



Formula 5G


(m = 1-2)




Formula 5H

(m = 2-6, q = 2-4)

wherein the several X's of a formula may be a combination of chelating agents selected from the group consisting of:




Formula 5I




Formula 5J

or




Formula 5K


and Y is a 3,2-HOPO or 1,2-HOPO structural unit selected from the group consisting of:



Formula 5L



Formula 5M




Formula 5N


where the free valency in each case indicates the preferred attachment point of the chelating group to a backbone.

In Formulae 5A to 5H, some of the chelating units X and Y may also be substituted by other chelating structural units. Representative examples of other chelating units include, but are not limited to: aminoacetic acid, hydroxamic acid, catechol, 2,3-dihydroxyterephthalamide or 3,4-HOPO.


Due to the presence of electron-withdrawing substituted carbamoyl group ortho to the hydroxy group of HOPO ring, compounds of Formulae 3 and 4 have lower pK_a s and more preferable coordination properties than corresponding HOPO ligands without the carbamoyl substituents. Their ring systems are also more able to withstand reduction or oxidation than corresponding HOPO ligands without the carbamoyl substituents. Similar to the case of catechoylamide complexes (Formula 6) and 1,2-HOPO-6-ylamide complexes (Formula 7), the strong hydrogen bonding between the amide proton and the adjacent oxygen donor, the hydroxy oxygen atom, also enhances the stability of the 3,2-HOPO complexes of this invention (Formula 8) as shown below:



Formula 6



Formula 7



Formula 8


wherein M is a metal ion with a high charge to radius ratio and the free valency in each case indicates the preferred attachment point of the chelating group to a backbone.

These chelating agents become very powerful chelators for metal ions with high charge to radius ratios.


Another important feature of the 3,2-HOPO ligands of this invention is that these compounds have a terminal R₁ group substituted on the HOPO ring nitrogen, which provides certain adjustable lipophilicity to the whole molecule, necessary for the ligand to display oral activity.

The lipophilic properties of the HOPO substituted compounds in combination with their relatively low pK_as make them effective oral agents, a highly desirable property for therapeutic agents. The new 3,2-HOPO compounds display high binding constants for ferric ion, on the order of 10²⁶ to 10²⁹ M⁻³, and pM values from 19 to 27 for the Fe(III)-tris(HOPO) complexes and are thus effective ligands for iron as well as for certain other ions with similar coordination properties (e.g., the actinide(IV) ions). These ligands are also surprisingly good chelating agents for the lanthanides.


Monomeric bidentate compounds of the invention include those given by the structure of Formula 9A, 9B and 9C.



Formula 9A



Formula 9B




Formula 9C

Formula 9A shows the acid form, while Formulae 9B and 9C show the benzyl protected amide form and deprotected amide form respectively. In these forms, R_1 is selected from the group consisting of: hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group. When R_1 is selected from these groups, the molecule is provided with adjustable lipophilicity. In Formula 9B and 9C, R' is selected from the group consisting of: hydrogen, C_{1-8} aliphatic hydrocarbon groups, and C_{1-8} aliphatic hydrocarbon groups substituted by a single carboxy, sulpho, sulphamoyl, N-methyl or N-ethyl sulphamoyl group, or an aryl group. The free valency in each case indicates the preferred attachment point of the chelating group to a backbone. Optionally, formulae 9A and 9C are in the form of a physiologically acceptable salt.

Although the new HOPO monomers display high affinity for ferric ions, for example, 1-methyl-4(1-propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone (Formula 9C, backbone = n-propyl, $R' = H$, $R_1 = \text{methyl}$), it has overall complex binding constants on the order of $10^{28.7} \text{ M}^{-3}$ for Fe(III). However, because of the 3:1 stoichiometry of the bidentate monomer /Fe complex, its stability is strongly dependent on its concentration (by the 3rd power). Generally, the pM concept was used to define the concentration of unchelated metal ion at physiological pH (7.4), and at chelator and metal ion concentrations (μmolar range) which are those expected in the plasma of a chelator-treated patient. The more effective chelator has the larger pM value. Since the multidentate 3,2-HOPO ligands have higher pM values than their bidentate analogues, they have stronger scavenging power for


1 iron and actinides *in vivo*. For example, the bidentate compound 1-methyl-4(1-
 2 propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone has a pM of 19.26 for Fe(III), while the
 3 hexadentate compound TREN-Me-3,2-HOPO (Formula 12, $m=1$) has a pM of 26.69 for
 4 Fe(III).

5 Tetradentate chelating agents of the present invention, which incorporate two 3,2-
 6 HOPO structural units, are given by Formula 10. These compounds form stable 2:1
 7 complexes with actinides, and are promising actinide sequestering agents.
 8



9
 10 Formula 10.

11 In Formula 10, two 3,2-HOPO structural units are linked to an aliphatic hydrocarbon
 12 molecular backbone $-(CH_2)_m-$, R_1 is as given above for the monomers of Formula 9, and m
 13 is an integer from 2 to 9. In a particularly preferred form, m is five, and the structure is "5-
 14 LI-Me-3,2HOPO" (1-Methyl-3-hydroxy-2(1H)-pyridinone structures separated by five
 15 methylene groups, some-what analogous in structure to previously known 5-LICAM, i.e.
 16 linear catechoylamide sequestering agents). Alternative molecular backbones of special
 17 interest are groups corresponding to a hydrocarbon group in which one or more carbon
 18 atoms are replaced by an oxygen or nitrogen atom. Such backbones are preferably more
 19 hydrophilic and the corresponding ligands will have better solubility in water. Specific
 20 examples of such tetradentate ligands are given by Formula 11, in which R_1 is as given
 21 above for the
 22




Formula 11

monomers of Formula 9, and m and n are each an integer from 2 to 4, and X may be oxygen or nitrogen (with a hydrogen, alkyl or aryl substitution).


Since hexadentate chelating agents form 1:1 complexes with iron, their stability has first order dependence on the ligand concentration. In other words, the hexadentate 3,2-HOPO ligands have strong scavenging power for iron at low concentration of ligand. The inventors surprisingly notice that the new tetradentate and hexadentate 3,2-HOPO ligands are not only excellent iron sequestering agents but also excellent actinide sequestering agents *in vivo*. This is surprising because actinides have coordination numbers greater than eight and therefore would not be expected to bind well to tetradentate or hexadentate chelating agents. This is not the case for tetradentate CAM or 1,2-HOPO sequestering agents, which are toxic and less effective *in vivo*.

Furthermore, because the new HOPOs are such effective chelators, it is possible that they can be used as MRI diagnosis complexing agents. As a specific example, see example 20, *infra*.

Hexadentate chelating agents of the present invention which incorporate three 3,2-HOPO structural units with a tripodal amine backbone are given by Formula 12 and 13. In both Formulae, R_1 is as given above for the monomers of Formula 9; and in Formula 12, m is an integer from 1 to 3.




Formula 12



Formula 13

Compounds of Formula 12 with $m = 1$ represents a particularly preferred embodiment of the invention, as it has been demonstrated to be non-toxic and extremely effective both in ferric chelation and in the decorporation of actinides such as Pu(IV), Am(III) and U(VI). This structure is abbreviated as TREN-Me-3,2-HOPO, similar in structure to previously known triscatechoylamide ligand TRENCAM.


Octadentate chelating agents provided by the present invention which incorporate four 3,2-HOPO structural units are given by Formula 14. This design is based on the siderophore analogues with 'H' shaped tetrapodal topology developed by the inventors, which proved to be predisposed towards metal binding. These chelating agents are especially suitable for binding actinide (IV) ions, because of their preferred high coordination number (eight or greater).




Formula 14

In Formula 14, R_1 is as given above for the monomers of Formula 9, and m and n are each an integer from 1 to 4.


The chelating agents of this invention also include mixed HOPO ligands which in addition to having at least one 3,2-HOPO structural unit, may also have other chelating structural units. Examples of these mixed chelating agents given by Formulae 15-17.



Formula 15




Formula 16



Formula 17

1
 2 Formula 15 gives a 3,2-HOPO-substituted analogue of ethylenediamine-N,N,N',N'-
 3 tetraacetic acid (EDTA) and Formula 16 gives a 3,2-HOPO substituted diethylenetriamine
 4 analogue with the Z moiety which is selected from the group consisting of: hydrogen, C₁₋₄₀
 5 hydrocarbon groups, 2-hydroxyethyl, 2-aminoethyl, and C₁₋₄ aliphatic hydrocarbon groups
 6 substituted by a single carboxy, sulpho, acrylamido or an aryl group; Formula 17 gives a
 7 3,2-HOPO-substituted analogue of desferrioxamine-B. In Formulae 15-17, R₁ is also as
 8 given above for the monomers of Formula 9. The chelating agent of Formula 16 with a long
 9 hydrocarbon chain as the Z group is a promising extractant for actinides, especially Am(III).


10 The chelating agents of this invention also include amine compounds which, in
 11 addition to having at least one 3,2-HOPO structural unit, are also substituted with 1,2-
 12 HOPO analogues and catechol analogues. Thus, in the compounds of Formulae 10-16
 13 above, the HOPO substituents could be replaced with the any of the structures given by
 14 Formulae 18 to 21, as long as one or more 3,2-HOPO substituents remain present on the
 15 chelating structure (where the free valency in each case indicates the preferred attachment
 16 point of the chelating group to a backbone).
 17




18

19 Formula 18


20



Formula 19



Formula 20




Formula 21

21 Also included in the present invention are chelating agents having polymeric backbones
 22 and at least one amine functionality to which a HOPO substituent is bonded through an amide-
 23 type linkage. Examples of suitable polymers here include, but are not limited to, poly(styrene-
 24 divinylbenzene), agarose, and polyacrylamide.

The present invention also relates to novel methods of synthesizing the aforementioned chelating agents as outlined below.

The novel 3,2-HOPO compounds (represented below by the monomeric compound) shown in Formula 9-17 may be conveniently synthesized according to Scheme 1.

Scheme 1



Wherein R = backbone, R₁ is selected from the group consisting of: hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted by a single halide, hydroxy, or carboxy group or an aryl group, and R' is selected from the group consisting of: hydrogen, C₁₋₈ aliphatic hydrocarbon groups, and C₁₋₈ aliphatic hydrocarbon groups substituted by a single carboxy, sulphy, sulphyamoyl, N-methyl or N-ethyl sulphyamoyl group, or an aryl group.

The 4-carboxylic acid derivative (Formula 9A) of 1-alkyl-3-hydroxy-2-pyridinone is prepared from a 1-alkyl-3-hydroxy-2-pyridinone. The latter, for example, 1-methyl-3-

1 hydroxy-2-pyridinone (Formula 22, R_1 = methyl) is a known compound. However, the
2 reported procedure is not safe and is neither convenient nor suitable for large scale
3 production. The reported procedure is to put 3-hydroxy-2(1H)-pyridinone and iodomethane
4 in a sealed glass tube and heat this mixture to 140° C for two days. However, the size of the
5 sealed glass tube is limited and yields only several grams of product. Furthermore, the
6 pressure in the sealed glass tube may cause it to explode, thereby releasing toxic fumes. If
7 the glass tube does not explode, the resultant material is treated with gaseous sulfur dioxide,
8 a corrosive and toxic gas. In the final step, the compound is purified by recrystallization
9 from petroleum ether, a method that is not safe, not convenient and is time consuming.

10 Because Formula 9A is an important precursor to the present invention, the inventors have
11 developed a safe and convenient procedure which can be used for large scale production as
12 follows. 3-Hydroxy-2(1H)-pyridinone and iodomethane (1:1.5 mol ratio) are placed in a
13 capped Teflon container, the container is put in a stainless steel Parr bomb and heated to
14 150° C for 2 days. This container may be 50 times larger than the sealed glass tube and will
15 not explode. The cooled bomb is opened and the resultant thick dark oil is mixed with
16 sodium sulfite (1:1.5 mol ratio), which is not corrosive and toxic (as is gaseous sulfur
17 dioxide) and dissolved in water. The solution is neutralized and then extracted with a
18 suitable solvent. The 1-methyl-3-hydroxy-2-pyridinone may then be purified with a flash
19 silica gel plug, which is much safer, convenient and time saving than recrystallization from
20 hot petroleum ether. The reported procedure yields approximately 6 grams each batch. The
21 present invention can yield approximately 300 grams by using a 1 liter capacity Parr bomb
22 each time.

23 The 4-carboxylic acid shown in Formula 9A (R_1 = H, alkyl) may then be prepared
24 from the 3,2-HOPO compound of Formula 22 (R_1 = H, alkyl) as follows. A quantity of the
25 3-hydroxy-2(1H)-pyridinone is mixed with anhydrous alkali metal carbonate, such as
26 sodium or potassium carbonate, in a preferred mol ratio of 1:3 to 1:5. The dried mixture is
27 then put in a Parr bomb and the bomb is then filled with dry carbon dioxide (850 psi) and

1 heated to 170-200° C for 2 days. The cooled bomb is opened and the resultant solid is
2 dissolved in water and treated with HCl, the 4-carboxylic acid may then be isolated as free
3 acid form e.g. by filtration recrystallization and dried (see Example 1).

4 The 3,2-HOPO ligands shown in Formulae 9C to 17 may be preferably prepared
5 from the reaction of an amine backbone and the active protected intermediates. Thus the 1-
6 alkyl-4-carboxy-3-hydroxy-2(1H)-pyridinone (Formula 9A) may conveniently be converted
7 to the protected acid (Formula 23) through the protection of the 3-hydroxy group.
8 Protection can be performed with an ether group, such as a benzyloxy group or a methoxy
9 group. Benzyloxy protection is preferred because it can be easily deprotected by
10 hydrogenation. Reaction of the protected acid with a compound to activate the acid (for
11 example: 2-mercapto-thiazoline or N-Hydroxysuccinimide (NHS)), in the presence of 1,3-
12 dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 or 25).
13 This is reacted with the amine compound which will provide the "backbone" of the
14 chelating agent at room temperature to give the protected 3,2-HOPO ligands generally as
15 viscous oils. They are purified preferably by extraction and/or column chromatography.
16 The hydroxy protecting groups may then be removed by hydrogenation and the final
17 product may be recrystallized from methanol, ethyl acetate, or water.

18 The 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone
19 (Formula 24) is a highly preferable intermediate: it is a bright yellow crystalline compound,
20 easy to be prepared and purified. Unlike other activated intermediates such as 3-benzyloxy-
21 1-methyl-4-(succinimidyloxy)carbonyl-2(1H)-pyridinone (Formula 25), it is stable and not
22 sensitive to alcohol, water, or even dilute inorganic acid and base. It selectively reacts with
23 primary amines to form amide products. The end of the reaction can be easily monitored by
24 the disappearance of its characteristic yellow color.

25 While many amines can be used in this reaction to effect production of 3,2-HOPO-
26 substituted chelating agents, preferred amines are those which correspond to the structures
27 of Formulae 9-17. Particularly preferred amines are the polyamines: 1,5-diaminopentane


1 (NH₂(CH₂)₅NH₂), 2,2'-oxybis(ethylamine), tris(2-aminoethyl)amine (see Formula 12,
2 m=2), tris(aminomethyl)-benzene (see Formula 13), N,N,N',N'-tetra(2-
3 aminoethyl)ethylenediamine, also known as PENTEN (see Formula 14, m=n=2), and the
4 monoamine desferrioxamine B (see Formula 17).

5 Other amines which may be used in the above synthetic procedure include
6 compounds generally given by Formulae 10-13 but having one or more 1,2-HOPO, 3,2-
7 HOPO and catechol moieties in addition to at least one 3,2-HOPO moiety. Organic
8 polymers having at least one amino group may also be used (e.g., agarose, polyacrylamide,
9 polystyrene derivatives and other similar compounds).



10 The novel 3,2-HOPO compounds (represented below by the monomeric compound)
11 shown in Formula 9-17 are also conveniently synthesized according to Scheme 1-1.
12
13

14 Scheme 1-1



15
16 Step 1:



1 Step 2A:

2
3
4
5

or Step 2B:



6

7 Wherein R = backbone, R₁ is selected from the group consisting of: hydrogen, C₁₋₄ aliphatic
 8 hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted by a single halide,
 9 hydroxy, or carboxy group or an aryl group, and R' is selected from the group consisting of:

1 hydrogen, C₁₋₈ aliphatic hydrocarbon groups, C₁₋₈ aliphatic hydrocarbon groups substituted
2 by a single carboxy, sulpho, sulphamoyl, N-methyl or N-ethyl sulphamoyl group, or an aryl
3 group, and W is generally Chloride, Bromide, or Iodide.

4 Step 1: The 4-carboxylic acid shown in Formula 9A' is prepared from the
5 commercially available 2,3-dihydroxypyridine (Formula 22 A) as follows. A quantity of the
6 3-hydroxy-2(1H)-pyridinone is mixed with anhydrous potassium carbonate in a preferred
7 mol ratio of 1:3 to 1:5. The dried mixture is then put in a Parr bomb and the bomb is then
8 filled with dry carbon dioxide (850 psi) and heated to 200° C for 2 days. The cooled bomb
9 is opened and the resultant solid is dissolved in water and treated with HCl, the 4-carboxylic
10 acid is then isolated in a free acid form, for example, by filtrating recrystallizing and drying.

11 The 3,2-HOPO ligands shown in Formulae 9C to 17 are preferably prepared from
12 the reaction of an amine backbone and the active protected intermediates. Thus the 4-
13 carboxy-3-hydroxy-2(1H)-pyridinone (Formula 9A') is conveniently converted to the fully
14 protected ester (Formula 9E and 9F) through the reaction with an alkylating agent, such as
15 benzyl chloride or methyl iodide, in the presence of a base, such as potassium carbonate.
16 Compounds 9E and 9F are easily separated by column chromatography.

17 Step 2A: Compound 9E is converted into the protected acid (Formula 23A), and
18 reaction of the protected acid with a compound to activate the acid (for example: 2-
19 mercapto-thiazoline or N-Hydroxysuccinimide (NHS)) in the presence of 1,3-
20 dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 A or 25A).
21 This is reacted with the amine compound which will provide the "backbone" of the
22 chelating agent at room temperature to give the protected 3,2-HOPO ligands generally as
23 viscous oils. They are purified preferably by extraction and/or column chromatography.
24 The hydroxy protecting groups are then removed by deprotection (for example using BBr₃
25 as a deprotecting agent) and the final product is recrystallized from methanol, ethyl acetate,
26 or water.

1 Step 2B: Similarly, compound 9F is converted into the protected acid (Formula
2 23B), and reaction of the protected acid with a compound to activate the acid (for example:
3 2-mercapto-thiazoline or N-Hydroxysuccinimide (NHS)), in the presence of 1,3-
4 dicyclohexylcarbodiimide (DCC) gives the activated intermediates (Formulae 24 B or 25B).
5 This is reacted with the backbone amine compound at room temperature to give the
6 protected 3,2-HOPO ligands generally as crystalline solids. They are purified preferably by
7 extraction and/or column chromatography. The hydroxy protecting groups are then
8 removed by deprotection (for example using BBr_3 as a deprotecting agent) and the final
9 product may be recrystallized from methanol, ethyl acetate, or water. In this way a series of
10 N-unprotected multidentate 3,2-HOPO ligands can be prepared conveniently.

11
12

13 Properties of the Novel Compounds

14

15 Physical Properties: The novel 3,2-HOPO compounds are white to pale-yellow in
16 color. They are not hygroscopic in general and are obtained as micro-crystalline or
17 amorphous solids. The monomers melt sharply, but the multidentate compounds
18 decompose slowly upon heating. The most distinctive feature of their NMR spectra is the
19 presence of two doublets in the aromatic region arising from the HOPO ring protons. The
20 two doublets appear at δ 6.4-6.6 and at δ 6.6-7.2 ppm. The I.R. of the isolated compounds
21 display a strong band at 1650-1680 cm^{-1} due to the amide group. In addition to that band
22 there are four strong bands in the region 1430-1600 cm^{-1} due to the ring C=C and C-N
23 stretching frequencies.

24

25 Chemical Properties: The 3,2-HOPO based amide compounds are in general
26 slightly to moderately soluble in water, except the simple monomers, such as compound 1-
27 methyl-4(1-propylcarbamoyl)-3-hydroxy-2(1H)-pyridinone (Formula 9C, R=1-propyl,
28 R'=H), which is very soluble in water as well as organic solvents. They are nearly neutral

1 (having pK_a 's on the order from 5 to 8), and the pH of saturated solutions typically are close
2 to neutral. These compounds form stable complexes with various metal ions, such as Fe^{3+} ,
3 Gd^{3+} , Am^{3+} , Pu^{4+} , etc.

4
5 Experimental Methods:
6

7 Infrared spectra were obtained with a Perkin-Elmer Model 283 spectrophotometer.
8 The NMR spectra were obtained using UCB 250 (250 MHz), BVX 300 (300 MHz) and AM
9 500 (500 MHz) spectrometers. Mass spectral data were obtained with an Atlas MS11; a
10 consolidated 12-110B, or a Kratos MS-50 spectrometer. The data can be tabulated as m/e.
11 Elemental analyses were performed by the microanalytical Laboratory, Department of
12 Chemistry, University of California, Berkeley.

13 Tris(3-aminopropyl)amine, 1,3,5-tris(aminomethyl)benzene, N,N,N',N'-tetrakis(2-
14 aminoethyl)-ethylenediamine (PENTEN or H(2,2)-amine) can be prepared by methods
15 described in the literature. N,N,N',N'-Tetrakis(2-aminoethyl)-1,3-propylenediamine
16 (H(3,2)-amine), and N,N,N',N'-tetrakis(2-aminoethyl)-1,4-butylenediamine (H(4,2)amine)
17 can be prepared in a manner similar to the preparation of PENTEN. Desferrioxamine B can
18 be obtained from Ciba-Geigy. Other reagents and items disclosed can be purchased from
19 Aldrich Chemical Co. and used as received.

20 Animal studies were completed using methods detailed in Radiation Protection
21 Dosimetry, in press, P. W. Durbin et al., "In Vivo Chelation of Am(III), Pu(IV), Np(V) and
22 U(VI) in Mice by TREN-(Me-3,2-HOPO)"; Radiation Protection Dosimetry, 17, No. 1, 1989,
23 p. 351, P. W. Durbin et al., "Removal of $^{238}Pu(IV)$ from Mice by Polycatecholate,
24 -Hydroxamate or -Hydroxypyridinonate Ligands"; Radiation Research, 99, 1984, p. 85, P. W.
25 Durbin et al., "Specific Sequestering Agents for the Actinides . . . "; Radiation Research, 99,
26 1984, p. 106, P. W. Durbin et al., "Removal of Pu and Am from Beagles and Mice . . . ";
27 Radiation Research, 81, 1980, p. 170, R. D. Lloyd et al., and P. W. Durbin et al., "Specific

1 Sequestering Agents for the Actinides . . . ". The foregoing articles are hereby incorporated
2 by reference.

3 Radionuclides used in the animal studies came from a variety of sources. However,
4 they can be purchased commercially. The $^{238}\text{Pu}(\text{IV})$ citrate and $^{241}\text{Am}(\text{III})$ citrate solutions
5 were prepared for animal injection by 8- to 10-fold dilution with 0.14M NaCl (pH 4) of
6 concentrated stock solutions (0.08M sodium citrate buffer) that had been held in frozen
7 storage at Lawrence Berkeley Laboratory (hereinafter LBL) for several years. [The $^{238}\text{Pu}(\text{IV})$
8 was originally obtained from D. R. Atherton at the University of Utah Radiobiology
9 Laboratory, Salt Lake City. The $^{241}\text{Am}(\text{III})$ solution had been obtained many years earlier
10 from the LBL Actinide Chemistry group.]

11 The $^{237}\text{Np}(\text{V})$ was obtained from J. Bucher of the LBL Actinide Chemistry group as
12 NpO_2Cl in 0.1M HCl. It was diluted to the desired radioactivity concentration in 0.14M NaCl
13 and the pH was adjusted to about 4.5 with NaOH just before use.

14 The ^{232}U was obtained from the Isotope Products Laboratory, Burbank, CA, and
15 $^{234,235}\text{U}$ was obtained as U metal from long held LBL storage. The two U sources were
16 combined and dissolved in 6N HNO_3 , dried, and redissolved in 0.1N HCl. The daughter
17 radioactivities were removed by elution from a Dowex-50X4 column (22 cm length, 0.7 cm
18 diameter, $1.5\text{ mL}\cdot\text{min}^{-1}$ flow rate) with 3.2N HCl. The U fractions (previously identified by a
19 trial run with $^{234,235}\text{U}$ alone) were combined, dried, and redissolved in 0.14M NaCl at pH 5.5.

20 All injections solutions, after dilution and pH adjustment, were sterilized by passing
21 through a $0.22\text{ }\mu\text{m}$ Millipore filter into 10 mL serum bottles fitted with rubber stoppers, and
22 frozen until used.

23 Solutions were calibrated by alpha scintillation counting (Packard Tri-Carb 460C,
24 Ecolume® scintillation fluid).

25 The current catalogue of Isotope Products Laboratory, Burbank, CA, lists for retail
26 sale: ^{238}Pu , ^{241}Am , ^{237}Np , and ^{232}U .

27

EXAMPLES

EXAMPLE 1: Preparation of 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone and related precursors

(1) 1-Methyl-3-hydroxy-2(1H)-pyridinone (Formula 22, R₁=methyl):

1-methyl-3-hydroxy-2(1H)-pyridinone is a known material; however the previous procedure for preparation is neither safe nor suitable for large scale production. Therefore, the inventors have developed a safe and convenient procedure which can be used for large scale or industrial production after minor modification. The details are described as follows:

3-hydroxy-2(1H)-pyridinone (34.44 g, 0.31 mol) and iodomethane (75 g, 0.53 mol) are placed in an 80 mL capped Teflon container (Caution: iodomethane is highly toxic), and put in a stainless steel Parr bomb and heated to 150° C for about 48-60 hours. The cooled bomb is opened and the excess iodomethane decanted. The resultant thick dark oil is mixed with sodium sulfite (64 g, 0.5 mol) and dissolved in 300 mL water to form a pale brown solution. The solution is neutralized to pH 7-8 and filtered to remove any insoluble impurity. The filtrate is then extracted with methylene chloride (4 x 100 mL). The combined extracts are dried, then applied to a flash silica gel plug (6 cm x 8 cm) and eluted with 4% methanol in methylene chloride. The solvent is rotary evaporated to give the title compound (24.3 g, 62.6%) as colorless crystals, mp. 129-130° C. ¹H NMR (250 MHz, CDCl₃): δ 3.621 (s, 3H), 6.144 (t, 1H, J=7.10), 6.79-6.85 (m, 2H), 7.27 (s, br, 1H). Anal. for C₆H₇NO₂ (125.129), Calcd.(found): C, 57.59 (57.23); H, 5.64 (5.70); N, 11.20 (10.93).

(2) 4-Carboxy-1-methyl-3-hydroxy-2(1H)-pyridinone (Formula 9A, R₁=methyl)

1-Methyl-3-hydroxy-2(1H)-pyridinone (1) (6.25 g, 50 mmol) is mixed with anhydrous potassium carbonate (36 g, 0.26 mol). The vacuum dried mixture is put in a Parr bomb which is then filled with dry carbon dioxide gas (850 psi) and heated to 175-185° C for 3 days. The cooled bomb is opened and the resultant pale yellow solid is dissolved in

1 ice water and acidified with 6N HCl to produce a beige crystalline product (7.42 g, 87.5%),
2 m.p. 243-245° C (dec). ¹H NMR (250 MHz, DMSO-*d*₆): δ 3.469 (s, 3H), 6.357 (d, 1H,
3 J=7.33), 7.166 (d, 1H, J=7.19), 7.27 (s,br, 1H). ¹H NMR (250 MHz, D₂O-NaOD): d 3.342
4 (s, 3H), 6.176 (d, 1H, J=6.94), 6.487 (d, 1H, J=7.00). Anal. for C₇H₇NO₄ (169.14): Calcd.
5 (found): C, 49.71 (49.74); H, 4.17 (4.30); N 8.28 (8.16).

6

7 (3) 3-Benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone (Formula 23, R₁=methyl)

8 4-Carboxy-1-methyl-3-hydroxy-2(1H)-pyridinone (6.8 g, 0.04 mol) is mixed with
9 benzyl chloride (12.1 g, 0.088 mol), anhydrous potassium carbonate (13.8 g, 0.1 mol) in
10 anhydrous dimethyl-formamide (DMF) (120 mL). The mixture is heated at 75-80° C under
11 N₂ in darkness for 16 hours. The reaction mixture is filtered and rotary evaporated to yield
12 a dark oil, which is purified by a silica gel plug as mentioned in 1-methyl-3-hydroxy-2(1H)-
13 pyridinone to give the 3-benzyloxy-4-benzyloxycarbonyl-1-methyl-2(1H)-pyridinone as a
14 pale yellow, thick oil. It is mixed with methanol (50 mL) and a 6 M NaOH solution (10
15 mL). The mixture is stirred at room temperature for 4 hours, then evaporated to dryness.
16 The residue is dissolved in water (100 mL), and acidified with 6 M HCl solution to pH 2 to
17 give the title compound (9.3 g 88.7%), as a white crystalline product, m.p. 152-153° C. ¹H
18 NMR (250 MHz, CDCl₃): δ 3.616 (s, 3H), 5.611 (s, 2H), 6.695 (d, 1H, J=7.13), 7.152 (d,
19 1H, J=7.16), 7.35-7.48 (m, 5H). Anal. for C₁₄H₁₃NO₄ · 0.2 H₂O (262.87), Calcd. (found):
20 C, 63.97 (64.05); H, 5.14 (5.14); N, 5.33 (5.18).

21

22 EXAMPLE 2: Preparation of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-
23 2(1H)-pyridinone (Formula 24, R₁=methyl)

24 To a solution of 3-benzyloxy-4-carboxy-1-methyl-2(1H)-pyridinone (1.05 g, 4
25 mmol), 2-mercaptothiazoline (0.50 g, 4.2 mmol) and a catalytic amount of 4-dimethyl-
26 aminopyridine (DMAP) in dry methylene chloride (50 mL), N,N'-
27 dicyclohexylcarbodiimide (DCC) (0.86 g, 4.2 mmol) is added. After stirring for 4 hours, the

1 dicyclohexylurea (DCU) solids are removed by filtration, the yellow filtrate is rotary
2 evaporated to give a yellow solid. Crystallization from isopropanol-methylene chloride
3 gives the title compound (1.16 g, 80.4%) as bright yellow crystalline plates, m.p. 149-150°
4 C. ¹H NMR (250 MHz, CDCl₃) δ 2.867 (t, 2H, J=7.32), 3.594 (s, 3H), 4.313 (t, 2H,
5 J=7.33), 5.301 (s, 2H), 6.107 (d, 1H, J=6.99), 7.126 (d, 1H, J=7.00), 7.31-7.45 (m, 5H).
6 Anal for C₁₇H₁₆N₂O₃S₂ Calcd. (found): C, 56.64 (56.36); H, 4.47 (4.47); N, 7.73 (7.73);
7 S, 17.78 (17.41).

8
9 **EXAMPLE 3: Preparation of 3-hydroxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone**
10 (Formula 9C, R₁=methyl, R=n-propyl, R'=H)

11 (1) 3-Benzyloxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (Formula 9B,
12 R₁=methyl, R=n-propyl, R'=H)

13 To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-
14 pyridinone (720 mg, 2 mmol) in dry methylene chloride (40 mL) is added n-propylamine
15 (0.18 mL, 2.2 mmol) while stirring. The disappearance of the yellow color indicates the end
16 of the amidation reaction. The reaction mixture is concentrated and loaded on a flash silica
17 gel column. Elution with 2-6% methanol in methylene chloride allows the isolation of
18 benzyl protected title compound (522 mg, 87%) as a colorless thick oil. ¹H NMR (250
19 MHz, CDCl₃): δ 0.794 (t, 3H, J=7.40), 1.333 (q, 2H, J=7.23), 3.184 (q, 2H, J=7.0), 3.605
20 (s, 3H), 5.383 (s, 2H), 6.816 (d, 1H, J=7.24), 7.123 (d, 1H, J=7.21), 7.30-7.50 (m, 5H), 7.92
21 (s, br, 1H).

22
23 (2) 3-Hydroxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (Formula 9C,
24 R₁=methyl, R=n-propyl, R'=H)

25 3-Benzyloxy-1-methyl-4(1-propylcarbamoyl)-2(1H)-pyridinone (301 mg, 1 mmol)
26 and 5% Pd/C catalyst (30 mg) are mixed with ethanol (15 mL), the mixture is stirred under
27 hydrogen (1 atm) at room temperature for three hours. After filtration, the filtrate is rotary

1 evaporated to give a pale pink solid. Crystallization from ethyl acetate gives the titled
2 compound (180 mg, 86%) as a colorless crystalline product, m.p. 163.5-165° C. ¹H NMR
3 (250 MHz, DMSO-*d*₆): δ 0.883 (t, 3H, J=7.41), 1.524 (q, 2H, J=7.30), 3.234 (q,
4 2H, J=6.57), 3.469 (s, 3H), 6.524 (d, 1H, J=7.43), 7.185 (d, 1H, J=7.42), 8.467 (s, br, 1H).
5 MS (+FAB, TG/G): 211.1 (MH⁺, 100%). Anal. for C₁₀H₁₃N₂O₃ (209.228), Calcd. (found):
6 C, 57.40 (57.44); H, 6.26 (6.63); N 13.39 (13.25).

7

8 **EXAMPLE 4:** Preparation of 1,3-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-
9 yl)carboxamido]propane (3-LI-Me-3,2-HOPO, Formula 10, R₁=methyl, m=3)

10 To a solution of 3-hydroxy-4-benzoyloxycarbonyl-1-methyl-2(1H)-pyridinone (1.1 g,
11 4.2 mmol), 2-mercaptothiazoline (0.52 g, 4.4 mmol), and a catalytic amount of DMAP in
12 dry methylene chloride (50 mL), DCC (0.90 g, 4.4 mmol) is added. The resulting yellow
13 mixture is stirred in darkness for four hours, and 1,3-propanediamine (0.15 g, 2 mmol) is
14 added neatly. The mixture is stirred overnight, and filtered to remove any DCU solids, the
15 filtrate is rotary evaporated and loaded onto a flash silica column. Elution with 2-6%
16 methanol in methylene chloride allows the separation of the benzyl-protected precursor
17 (0.98 g) as a pale yellow thick oil. It is dissolved in glacial acetic acid (20 mL) and
18 hydrogenated by using 10% Pd on charcoal as a catalyst. Filtration followed by rotary
19 evaporation gives a pale brown residue which is recrystallized from methanol to give the
20 title compound (555 mg, 73.3%) as a beige powder, m.p. 268-271° C (dec). ¹H NMR (300
21 MHz, DMSO-*d*₆): δ 1.757 (t, 2H), 3.327 (q, 4H), 3.469 (s, 6H), 6.503 (d, 2H, J=7.24),
22 7.193 (d, 2H, J=7.28), 8.483 (s, br, 2H), 11.7 (s, br, 2H). MS (+FAB, NBA): 377.2 (MH⁺,
23 17%), 399.2 (MNa⁺, 11%). Anal. for C₁₇H₂₀N₄O₆ (376.375), Calcd. (found): C, 54.25
24 (54.17); H, 5.35 (5.49); N, 14.88 (14.59).

25

26

1 **EXAMPLE 5:** Preparation of 1,4-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-
2 yl)carboxamido]butane (4-LI-Me-3,2-HOPO, Formula 10, R₁=methyl, m=4)

3 This compound is prepared by the procedure of example 4, except 1,4-
4 butanediamine (160 mg, 1.8 mmol) is used instead of 1,3-propanediamine. Separation and
5 purification of the benzyl-protected precursor are performed as described above, the pure
6 precursor is recrystallized from methanol as a white crystalline solid, m.p. 189-190° C. It is
7 deprotected by catalytic hydrogenation as described above. The title compound is
8 recrystallized from methanol to give a beige solid product (462 mg, 68.7%), m.p. 265° C.
9 (dec). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.541 (s, br, 2H), 3.308 (s, br, 4H), 3.463 (s, 6H),
10 6.515 (d, 2H, J=7.31), 7.187 (d, 2H, J=7.27), 8.483 (t, br, 2H, J=5.34). MS (+FAB, NBA):
11 391.3 (MH⁺, 100%), 413.1 (MNa⁺, 25%). Anal. for C₁₈H₂₂N₄O₆·0.5 H₂O (399.41),
12 Calcd. (found): C, 54.13 (54.67); H, 5.80 (5.91); N, 14.02 (13.58).

13
14 **EXAMPLE 6:** Preparation of 1,5-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-
15 yl)carboxamido]pentane (5-LI-Me-3,2-HOPO, Formula 10, R₁=methyl, m=5)

16 This compound is prepared by the procedure of example 4, except 1,5-
17 pentanediamine (0.21 g, 2mmol) is used instead of 1,3-propanediamine. Separation and
18 purification of the benzyl-protected precursor are performed as described above, the pure
19 precursor is separated as a pale yellow oil. It is deprotected by catalytic hydrogenation as
20 described above. The deprotected product is recrystallized from methanol to give the title
21 compound (530 mg, 65.7%) as white scale-like micro crystalline product. m.p. 225-6° C
22 (dec). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.32 (m, 2H), 1.527 (qin, 4H, J=7.17), 3.276 (q,
23 4H, J=6.49), 3.464 (s, 6H), 6.509 (d, 2H, J=7.33), 7.183 (d, 2H, J=7.34), 8.459 (t, br, 2H,
24 J=5.52). MS (+FAB, NBA): 405 (MH⁺, 100%), 427.1 (MNa⁺, 25%). Anal. for
25 C₁₉H₂₄N₄O₆·0.56H₂O (415.24), Calcd. (found): C, 54.96 (54.89); H, 6.12 (5.99); N, 13.45
26 (13.27).

27

1 **EXAMPLE 7:** Preparation of 1,6-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-
2 yl)carboxamido]hexane (6-LI-Me-3,2-HOPO, Formula 10, R_1 =methyl, $m=6$)

3 This compound is prepared by the procedure of example 4, except 1,6-
4 hexanediamine (220 mg, 1.9 mmol) is used instead of 1,3-propanediamine. Separation and
5 purification of the benzyl-protected precursor are performed as described above, the pure
6 precursor is recrystallized from methanol as a white crystalline solid, m.p. 179-180° C. It is
7 deprotected by catalytic hydrogenation as described above. The title compound is
8 recrystallized from methanol to give a white solid product (530 mg, 73.3%), m.p. 240-1° C.
9 (dec). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.32 (s, br, 4H), 1.501 (t, br, 4H, $J=6.62$), 3.258
10 (q, 4H, $J=6.55$), 3.452 (s, 6H), 6.502 (d, 2H, $J=7.22$), 7.183 (d, 2H, $J=7.34$), 8.455 (t, br, 2H,
11 $J=5.36$), 11.8 (s, br). MS (+FAB, NBA): 419.2 (MH⁺, 10%), 441.2 (MNa⁺, 29%), 463.2 (M
12 + Na⁺ - H⁺, 15%). Anal. for C₂₀H₂₆N₄O₆ · 0.25 H₂O (422.96), Calcd. (found): C, 56.79
13 (57.03); H, 6.31 (6.41); N, 13.24 (12.95).

14

15 **EXAMPLE 8:** Preparation of 1,5-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-
16 yl)carboxamido]-3-oxypentane (5-LI-O-Me-3,2-HOPO, Formula 11, X=O, $m=n=2$)

17 This compound is prepared by the procedure of example 4, except 2,2'-
18 oxybis(ethylamine) dihydrochloride (0.25 g, 1.4 mmol) is used instead of 1,3-
19 propanediamine. Separation and purification of the benzyl-protected precursor are
20 performed as described above, the pure precursor is separated as a pale yellow oil. It is
21 deprotected by catalytic hydrogenation as described above. The title compound is
22 recrystallized from methanol to give a white solid product (510 mg, 89%), m.p. 205° C.
23 (dec). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.327 (t, 4H), 3.404 (s, 6H), 3.488 (t, 4H,
24 $J=5.32$), 6.452 (d, 2H, $J=7.33$), 7.107 (d, 2H, $J=7.31$), 8.483 (s, br, 2H). MS (+FAB, NBA):
25 407.2 (MH⁺, 100%), 429.2 (MNa⁺, 72%). Anal. for C₁₈H₂₂N₄O₇ (408.20), Calcd. (found):
26 C, 53.19 (53.01); H, 5.48 (5.50); N, 13.72 (13.62).

27

1 EXAMPLE 9: Preparation of N,N,N,-tris[(3-benzyloxy-1-methyl-2-oxo-1,2-
2 dihydropyridin-4-yl)carboxamidoethyl]-amine (TREN-Me-3,2-HOPO, Formula 12, m=1)

3 To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-
4 pyridinone (Formula 24, 1.44 g, 4 mmol) in methylene chloride (50 mL), freshly distilled
5 tris(2-aminoethyl)amine (TREN) (0.18 g, 1.2 mmol) is added, the mixture is stirred
6 overnight and then rotary evaporated and loaded onto a flash silica column. Elution with 2-
7 7% methanol in methylene chloride allows for isolation of the pure benzyl-protected
8 precursor as a pale yellow oil. It is dissolved in glacial acetic acid (10 mL) and
9 hydrogenated by using 10% Pd on charcoal as catalyst. Filtration followed by rotary
10 evaporation gives a pale brown residue which is recrystallized from water to give the title
11 compound (486 mg, 67.1%) as a pale yellow crystalline solid, m.p. 130-2° C (dec). ¹H
12 NMR (250 MHz, DMSO-*d*₆): δ 2.296 (t, 6H, J=5.97), 3.072 (q, 6H, J=5.82), 3.449 (s, 9H,
13 NCH₃), 6.458 (d, 3H, J=7.24), 7.122 (d, 3H, J=7.27), 8.46 (t, br, 3H, J=5.3). ¹H NMR (250
14 MHz, D₂O-NaOD): δ 2.901 (t, 6H, J=6.26), 3.450 (s, 9H), 3.520 (t, 6H, J=6.24), 6.568 (d,
15 3H, J=7.29), 6.609 (d, 3H, J=7.21). MS (+FAB, NBA): 600.3 (MH⁺). Anal. for
16 C₂₇H₃₃N₇O₉·1.5 H₂O (626.634) Calcd.(found): C, 51.75 (51.84); H 5.79 (5.54); N 15.64
17 (15.59).

18
19 EXAMPLE 10: Preparation of N,N,N,-tris[(3-benzyloxy-1-methyl-2-oxo-1,2-
20 dihydropyridin-4-yl)carboxamidopropyl]-amine (TRPN-Me-3,2-HOPO, Formula 12, m=2)

21 This compound is prepared by the procedure of TREN-Me-3,2-HOPO, except tris(3-
22 aminopropyl)amine (TRPN) (0.16 g, 1.1 mmol) is used instead of TREN. Separation and
23 purification of the benzyl-protected precursor are performed as described in example 9. The
24 title compound (392 mg, 56.6%) is obtained by catalytic hydrogenation deprotection
25 followed by precipitation from methanol/ether mixture and collected by filtration as a pale,
26 greenish-yellow solid, m.p. 165° C (dec) ¹H NMR (250 MHz, DMSO-*d*₆): δ 1.710 (s, br
27 6H), 2.660 (s,br, 6H), 3.302 (s,br, 6H), 3.429 (s, 9H), 6.485 (d, 3H, J=7.30), 7.065 (d, 3H,

1 J=7.30), 8.80 (s br, 3H). ¹H NMR (250 MHz, D₂O-NaOD): δ 1.756 (s, br 6H), 2.592 (s, br,
2 6H), 3.330 (s, br, 6H), 3.374 (s, 9H), 6.516 (d, 3H, J=7.27), 6.617 (d, 3H, J=7.17). MS
3 (+FAB, TG/G): 642.2 (MH⁺, 85%). Anal. for C₃₀H₃₉N₇O₉·H₂O (659.707), Calcd.(found):
4 C, 54.62 (54.40); H, 6.26 (6.27); N, 14.86 (14.82).

5

6 EXAMPLE 11: Preparation of N,N,N,-tris[(3-hydroxy-1-methyl-2-oxo-1,2-
7 dihydropyridin-4-yl)carboxamidoethyl]-amine (ME-Me-3,2-HOPO, Formula 13)

8 To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-
9 pyridinone (Formula 24, 400 mg, 1.1 mmol) in methanol (10 mL), a solution of
10 mesitylenetriamine trihydrochloride (82 mg, 0.3 mmol) in pyridine/water (4:1, 10 mL) is
11 added, the mixture is stirred overnight and rotary evaporated to dryness. The residue is
12 dissolved in methylene chloride and loaded onto a flash silica column. Elution with 2-8%
13 methanol in methylene chloride allows for isolation of the pure benzyl-protected precursor
14 as a pale yellow oil, which solidifies upon standing. The title compound (118 mg, 58.3%) is
15 obtained by catalytic hydrogenation deprotection of the precursor followed by
16 recrystallization from methanol as a white solid, m.p. 168-70° C (dec). ¹H NMR (300 MHz,
17 DMSO-*d*₆): δ 3.470 (s, 9H), 4.463 (d, 6H, J=5.54), 6.495 (d, 3H, J=7.26), 7.147 (s, 3H),
18 7.159 (d, 3H, J=7.64), 8.913 (t, 3H, J=5.75). MS (+FAB, NBA): 619.2 (MH⁺, 100%),
19 641.2 (MNa⁺, 20%). Anal. for C₃₀H₃₀N₆O₉·1.9 H₂O (652.84), Calcd.(found): C, 55.19
20 (55.31); H, 5.19 (5.19); N, 12.87 (12.62).

21

22 EXAMPLE 12: Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-
23 dihydropyridin-4-yl)carboxamido-ethyl]-ethylenediamine (H(2,2)-Me-3,2-HOPO, Formula
24 14, m=n=2)

25 To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-
26 pyridinone (Formula 24, 1.44 g, 4 mmol) in methylene chloride (50 mL), N,N,N',N'-
27 tetrakis(2-aminoethyl)ethylenediamine (PENTEN) (258 mg, 0.9 mmol) is added. After

1 stirring for four hours, the mixture is filtered and evaporated to dryness. The residue is
2 loaded onto a flash silica column. Elution with 3-8% methanol in methylene chloride
3 allows for isolation of the pure benzyl-protected precursor as a pale yellow oil. It is
4 dissolved in glacial acetic acid (20 mL), 20% Pd(OH)₂ on charcoal catalyst is added and the
5 mixture is hydrogenated under 400 psi at room temperature overnight. Filtration followed
6 by rotary evaporation gives a pale brown residue which is recrystallized from methanol to
7 give the title compound (397 mg, 52.9%) as a white powder, m.p. 270° C (dec). ¹H NMR
8 (250 MHz, DMSO-*d*₆): δ 2.663 (s, br, 12H), 3.35 (m, br, 8H), 3.436 (s, 12H), 6.465 (d, 4H,
9 J=7.26), 7.093 (d, 4H, J=7.35H), 8.5 (s, br, 4H). MS (+FAB, NBA): 837.3 (MH⁺, 100%).
10 Anal. for C₃₈H₄₈N₁₀O₁₂·H₂O (854.884), Calcd.(found): C, 53.39 (53.29); H, 5.89 (5.71); N
11 16.38 (16.10).

12
13 **EXAMPLE 13:** Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-
14 dihydropyridin-4-yl)carboxamido-ethyl]-propylenediamine (H(3,2)-N-Me-3,2-HOPO,
15 Formula 14, m=3, n=2)

16 This compound is prepared by the procedure of H(2,2)-Me-3,2-HOPO, except
17 N,N,N',N'-tetrakis(2-aminoethyl)-propylenediamine (H(3,2)-amine) (76 mg, 0.25 mmol) is
18 used instead of PENTEN. Separation and purification of the benzyl-protected precursor are
19 performed as described in example 12. The title compound (110 mg, 51.5%) is obtained by
20 catalytic hydrogenation deprotection of the precursor followed by recrystallization from
21 methanol as a greenish pale yellow solid, m.p. 141° C (dec). ¹H NMR (300 MHz, DMSO-
22 *d*₆): δ 1.639 (s, br, 2H), 2.644 (s, br, 4H), 2.724 (s, br, 8H), 3.400 (s, br, 8H), 3.424 (s, 12H),
23 6.448 (d, 4H, J=7.19), 7.040 (d, 4H, J=7.23), 8.778 (s, br, 4H). MS (+FAB, NBA): 851.3
24 (MH⁺, 45%). Anal. for C₃₉H₅₀N₁₀O₁₂·1.2H₂O (875.52), Calcd.(found): C, 53.69 (53.70);
25 H, 6.05 (5.98); N, 16.05 (16.09).

1 EXAMPLE 14: Preparation of N,N,N',N'-tetrakis[(3-hydroxy-1-methyl-2-oxo-1,2-
2 dihydropyridin-4-yl)carboxamido-ethyl]-butylenediamine (H(4,2)-Me-3,2-HOPO, Formula
3 14, m=4, n=2)

4 This compound is prepared by the procedure of H(2,2)-Me-3,2-HOPO, except
5 N,N,N',N'-tetrakis(2-aminoethyl)-butylenediamine (H(4,2)-amine) (80 mg, 0.25 mmol) is
6 used instead of PENTEN. Separation and purification of the benzyl-protected precursor are
7 performed as described in example 12. The title compound (125 mg, 58.3%) is obtained by
8 catalytic hydrogenation deprotection followed by recrystallization from methanol as a pale
9 yellow solid, m.p. 124° C (dec). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.656 (s, br, 2H),
10 2.719 (s, br, 4H), 2.844 (s, br, 8H), 3.411 (s, br, 8H), 3.450 (s, 12H), 6.403 (d, 4H, J=7.19),
11 6.969 (d, 4H, J=7.32), 8.811 (s, br, 4H). MS (+FAB, NBA): 865.4 (MH⁺, 66%). Anal. for
12 C₄₀H₅₂N₁₀O₁₂ · 2.2H₂O (904.56), Calcd.(found): C, 53.06 (53.11); H, 6.28 (6.28); N, 15.47
13 (15.48).

14

15 EXAMPLE 15: Preparation of DFO-1-Me-3,2-HOPO (Formula 17)

16 (1) Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex

17 The mesylate salt of DFO (Desfera, 2.63 g, 4 mmol) and FeCl₃·6 H₂O (1.08 g, 4
18 mmol) are dissolved in methanol (120 mL) in a 250 mL round flask. To this purple-red
19 solution, KOH solution (1.018 N KOH in methanol (Aldrich), 11.7 mL) is added slowly,
20 while stirring. To the above red Fe(III)-DFO complex (free amine species) solution, a
21 solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-pyridinone
22 (Formula 24, 1.44 g, 4 mmol) in methanol (50 mL) is added slowly, while stirring and the
23 mixture is then stirred overnight. TLC on silica reveals the formation of benzyl protected
24 Fe(III)-1-Me-3,2-HOPO-DFO complex. The red mixture is evaporated to dryness, then
25 loaded on a flash silica column and gradient eluted with 4-20% methanol in methylene
26 chloride. The main red fraction which shows only one spot on TLC (silica) plate is
27 collected and evaporated to dryness, yielding 2.73 g (3.08 mmol, 77.2% based on DFO) of

1 Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex. Anal for $C_{39}H_{56}N_7O_{11}Fe \cdot 2 H_2O$ (890.805),
2 Calcd. (found): C, 52.58 (52.99); H, 6.79 (7.25); N, 11.00 (11.19); Fe, 6.26 (5.97).

3

4 (2) Bn-DFO-1-Me-3,2-HOPO

5 The above Fe(III)-Bn-DFO-1-Me-3,2-HOPO Complex (2.56 g, 3.0 mmol) is
6 dissolved in a minimum amount of water and the pH is adjusted to above 13 with a 12 M
7 NaOH solution. The turbid solution is then filtered to remove the brown $Fe(OH)_3$
8 precipitate. The slight yellow filtrate is acidified with 6 M HCl, at which point the protected
9 DFO-Me-3,2-HOPO separates as very thick pale yellow oily material. After cooling, the
10 oily product is solidified, it is triturated with the mother liquor and then filtered. The title
11 compound (1.24 g, 51.7%) is obtained after washing with cold water, methanol and drying
12 as a white solid product, m.p. 110-2° C. 1H NMR (300 MHz, $DMSO-d_6$): δ 1.2-1.5 (m,
13 18H), 1.967 (s, 3H), 2.276 (t, $J=7.04$, 4H), 2.586 (t, $J=6.83$, 4H), 3.007 (q, $J=6.14$, 2H),
14 3.456 (t, $J=6.94$, 6H), 5.203 (s, 2H), 6.262 (d, 1H, $J=7.02$), 7.3-7.5 (m, 5H), 7.528 (d, 1H,
15 $J=7.03$), 7.807 (t, br, 2H, $J=5.04$), 8.220 (t, br, $J=5.41$), 9.6 (s, br, 3H). MS (+FAB, NBA):
16 m/e 802.4 (MH^+ , 100%). Anal. for $C_{39}H_{59}N_7O_{11} \cdot H_2O$ (819.966), Calcd. (found): C, 57.13
17 (57.37); H, 7.50(7.64); N, 11.96 (11.78).

18

19 (3) DFO-Me-3,2-HOPO (Formula 17)

20 Bn-DFO-Me-3,2-HOPO (0.82 g, 1 mmol) is suspended in methylene chloride (20
21 mL) in a schlenk flask with a teflon stopcock. Under a flow of argon, the suspension is
22 cooled to 0° C before boron tribromide (1.9 mL, 20 mmol) is injected. The yellow slurry is
23 stirred at room temperature for 72 hours before pumping off the excess BBr_3 and CH_2Cl_2 .
24 The remaining pale yellow solid is suspended in cold water. The raw product is collected
25 by filtration, and then dissolved in a 1 M NaOH solution. The solution is then acidified to
26 pH 3 and the resultant precipitate is filtered off and dried to give the title compound (0.37 g,
27 53%) as a white solid, m.p. 166-8° C (dec). 1H NMR (300 MHz, $DMSO-d_6$) δ 1.20-1.52

1 (m, 18H), 1.962 (s, 3H), 2.261 (t, 4H, J = 7.18), 2.571 (t, 4H, J = 7.14), 2.993 (q, 4H, J =
2 6.32), 3.251 (q, 2H, J = 6.48), 3.450 (t, 6H, J = 7.34), 3.458 (s, 3H), 6.514 (d, 1H, J = 7.24),
3 7.182 (d, 1H, J = 7.30), 7.778 (t, br, 2H, J = 5.17), 8.484 (t, br, 1H, J = 5.02), 9.617 (s, 2H),
4 9.660 (s, 1H). MS (+FAB, NBA): 712.4(MH⁺, 85%), 734.4 (MNa⁺, 82%), 696.4 (60%).
5 Anal for C₃₂H₅₃N₇O₁₁ (711.824), Calcd. (found): 53.99 (54.19), 7.50 (7.53), 13.77
6 (13.48).
7

8 **EXAMPLE 16: Preparation of TREN-bis-Me-3,2-HOPO-bis-acetic acid (Formula 15)**

9 (1) N,N-Bis[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl-N-
10 (2-aminoethyl)amine (Bn-TREN-Bis-Me-3,2-HOPO, Formula 16, Z=CH₂CH₂NH₂)

11 To a solution of 3-benzyloxy-1-methyl-4-(2-thioxothiazolidin-1-yl)carbonyl-2(1H)-
12 pyridinone (Formula 24, 3.2 g, 8.8 mmol) in CH₂Cl₂ (150 mL), a solution of TREN (0.63 g,
13 4.4 mmol) in 150 mL CH₂Cl₂ is added drop by drop over 16 hours. The reaction mixture is
14 concentrated, loaded on a flash silica gel column (φ 40 x 80 mm), and eluted with 4%
15 methanol in methylene chloride to separate 2-mercaptothiazoline and other byproducts. The
16 title compound remains on the top of the column and is separated by further gradient elution
17 with 4-6% CH₃OH + 0.4% Triethylamine. The appropriate fractions are collected and
18 evaporated to give 1.98 g (71%) of a white solid. This is a very useful intermediate to
19 synthesize various mixed 3,2-HOPO chelating agents. ¹H NMR (300 MHz, CDCl₃): δ
20 2.347(m, 6H), 2.484(m, 2H), 3.198 (q, 4H, J=5.97), 3.591(s, 6H), 5.324 (s, 4H), 6.714 (d,
21 4H, J=7.20), 7.117 (d, 4H, J=7.20), 7.27-7.43 (m, 10H), 7.978 (s br, 2H).
22

23 (2) Ethylenediamine-N,N-bis[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-
24 carboxamidoethyl]-N',N'-diacetic acid (TREN-bis-Me-3,2-HOPO-bis-acetate, Formula 15)

25 N,N-Bis[(3-benzyloxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamido-ethyl-
26 N-(2-aminoethyl)amine (2.0 g, 3.2 mmol), benzyl 2-bromoacetate (2.29 g, 10 mmol) and
27 anhydrous K₂CO₃ (1.5 g, 10 mmol) are combined in dry THF (50 mL). The stirred mixture

1 is warmed to 60° C overnight under nitrogen. After cooling to room temperature, the
2 reaction mixture is filtered, the filtrate is rotary evaporated and applied to a flash silica gel
3 column. Elution with 0.5–4.0% CH₃OH in CH₂Cl₂ produces a pale yellow thick oil as pure
4 benzyl protected precursor. It is dissolved in glacial acetic acid (20 mL), 20% Pd(OH)₂ on
5 charcoal catalyst (200 mg) is added and the mixture hydrogenated under 400 psi at room
6 temperature overnight. Filtration followed by rotary evaporation gives a pale brown residue
7 which is recrystallized from methanol to give the title compound (0.93 g, 53.1%) as a white
8 powder, m.p. 194–6° C (dec). ¹H NMR (500 MHz, D₂O): δ 3.291 (s, br, 4H), 3.367 (s, 6H),
9 3.38–3.39 (m, br, 2H), 3.40–3.42 (m, br, 2H), 3.542 (s, br, 4H), 3.791 (s, NH), 6.351 (d, 2H,
10 J=4.35), 6.839 (d, 2H, J=4.34). MS (+FAB, TG/G): 565.2(MH⁺, 100%), 587.2 (MNa⁺,
11 20%). Anal for C₂₄H₃₂N₆O₁₀·1.2 H₂O (582.824), Calcd. (found): C, 49.17(49.68); H,
12 5.91 (6.15); N, 14.33 (13.98).

13

14 **EXAMPLE 17: Preparation of Thorium (IV) Complex with 3-Hydroxy-1-methyl-4-(1-**
15 **propylcarbamoyl)-2(1H)-pyridinone**

16 To a solution of 1-Me-3,2-HOPO propylamide (Formula 9B, R=methyl, R'=H, 84
17 mg, 0.40 mmol) in dry acetonitrile (10 mL), a solution of thorium acetylacetonate (63 mg,
18 0.1 mmol) in acetonitrile (10 mL) is added while stirring. The clear mixture solution turns
19 turbid after a few minutes, it is refluxed overnight under nitrogen. The resultant precipitate
20 is filtered off and dried to give the title compound (66 mg, 88%) as a beige solid, m.p. 216–
21 8° C. ¹H NMR (300 MHz, DMSO): δ 0.666(t, 12H, J=7.39), 1.158(q, 8H, J=7.17),
22 2.956(q, 8H, J=6.47), 3.487 (s, 6H), 6.819 (d, 2H, J=7.03), 6.974 (d, 2H, J=7.19), 9.397(t,
23 4H, J=5.57). MS (+FAB, TG/G) 1069.7 (ThL₄H⁺, 50%), 859.3(ThL₃⁺, 100%). Anal for
24 ThC₄₀H₅₂N₈O₁₂·2.5H₂O (1114.43), Calcd. (found): C, 43.11(43.13); H, 5.15 (4.91); N,
25 10.05 (9.79).

26

1 **EXAMPLE 18:** Preparation of Ferric Ion Complex with 1,3-Bis[(3-hydroxy-1-methyl-2-
2 oxo-1,2-dihydropyridin-4-yl)carboxamido]propane

3 To a suspension of 3-LI-Me-3,2-HOPO (Formula 10, $m=3$, 245 mg, 0.65 mmol) in
4 dry methanol (10 mL), 0.65 mL of 1.018 M KOH/methanol (Aldrich) is added to make a
5 clear solution. A solution of ferric acetylacetonate complex (140 mg, 0.4 mmol) in dry
6 methanol (10 mL) is added to the above ligand solution while stirring and results in a deep
7 red color. The solution is evaporated under vacuum to give a black-red powdery solid,
8 which is loaded on a lipophilic sephadex (LH 20) column and eluted with methanol. The
9 deep red band is collected and rotary evaporated to give the title complex (160 mg, 65%) as
10 a powdery red-black solid. MS (+FAB, NBA): 1235.7 (MH^+ , 100%), shows typical isotope
11 distribution for iron compounds. Anal for $Fe_2C_{51}H_{54}N_{12}O_{18} \cdot H_2O$ (1252.79), Calcd.
12 (found): C, 48.89 (48.66); H, 4.50 (4.71); N, 13.41 (13.23); Fe, 8.91 (8.75).
13

14 **EXAMPLE 19:** Preparation and Crystal Structure of Ferric Ion Complex with N,N,N,-
15 Tris[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine
16 (Fe(III)-TREN-3,2-HOPO complex)

17 To a solution of TREN-Me-3,2-HOPO (63 mg, 0.10 mmol) in distilled water (20
18 mL), a solution of $FeCl_3$ (27 mg, 0.1 mmol) in water (5 mL) is added while stirring. The
19 purple-red mixture solution is neutralized with saturated $NaHCO_3$ solution. The complex
20 deposits upon standing overnight. It is filtered out and dried to give the title complex (62
21 mg, 95%) as black-red crystals. MS (+FAB, NBA): 653.3 (MH^+ , 61%), shows an isotopic
22 distribution typical for iron complexes. Anal. for $FeC_{27}H_{30}N_7O_9 \cdot H_2O$ (670.45), Calcd.
23 (found): C, 48.37 (48.36); H, 4.81 (5.01); N, 14.62 (14.38).

24 Crystals of this compound suitable for x-ray diffraction are prepared by vapor
25 diffusion of ether into its wet DMF solution. Its chemical formula is $2FeC_{29}H_{30}N_7O_9 \cdot$
26 $2H_2O \cdot C_3H_7NO$. Its crystal structure is shown in Figure 1 and the crystallographic data and
27 parameters for this compound are shown in Table 1. The structure reveals extensive

1 delocalization and a strong hydrogen bonding between the amide proton and its adjacent
2 HOPO oxygen donor, as shown in Formula 8.

3
4 Table 1.
5

6 Crystallographic Data and Parameters for $2\text{FeO}_9\text{N}_7\text{C}_{27}\text{H}_{30}\cdot 2\text{H}_2\text{O}\cdot \text{C}_3\text{H}_7\text{NO}$
7

8		
9	Formula:	$2\text{FeO}_9\text{N}_7\text{C}_{27}\text{H}_{30}\cdot 2\text{H}_2\text{O}\cdot \text{C}_3\text{H}_7\text{NO}$
10	Formula Weight(amu)	1487.13
11	Temperature (° C)	-116
12	Crystal System	triclinic
13	Space Group (#)	$\text{P}\bar{1}$ (#2)
14	Cell Constants ^a	
15	a (Å)	12.774(3)
16	b (Å)	12.838(4)
17	c (Å)	20.740(7)
18	α (°)	91.33(3)
19	β (°)	92.92(2)
20	γ (°)	102.72(3)
21	Z	4
22	V(Å ³)	3311(3)
23	Abs. Coeff., μ_{calc} (cm ⁻¹)	5.46
24	d_{calc}	1.49
25	F(000)	1540
26	Crystal dimensions (mm)	0.65 x 0.50 x 0.20 mm
27	Radiation	Mo-K α ($\lambda=0.71073$)
28	Diffractionmeter	Enraf-Nonius CAD-4
29	h, k, l range collected	0 \rightarrow 13, -13 \rightarrow +13, -22 \rightarrow +22
30	2 θ range	3° - 45°
31	Scan Type	Omega-2Theta
32	Scan speed (θ , °/min.)	5.49°/min
33	Reflections collected	8625
34	Unique reflections:	8625
35	Reflections with ($F_o^2 > 3\sigma(F_o^2)$)	6168
36	Number of parameters	901
37	Data/parameter ratio	6.8
38	$R=[\sum \Delta F /\sum F_o]$	0.081
39	$R_w=[\sum w(\Delta F)^2/\sum w F_o^2]$	0.103
40	GOF	2.994
41	Final Diff. ρ_{max} (e ⁻ /Å ³)	+1.3 ^b
42		

43 ^aUnit cell parameters and their esd's were derived by a least-squares fitting of the setting angles of 24 reflections in
44 the range $9.9^\circ \leq 2\theta \leq 13.9^\circ$.

45 ^bLocated near Fe 2.

1 **EXAMPLE 20: Preparation and Crystal Structure of Gadolinium (III) Ion Complex with**
2 **N,N,N,-Tris[(3-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)carboxamidoethyl]-amine**
3 **(Gd(III)-TREN-3,2-HOPO complex)**

4 To a solution of TREN-Me-3,2-HOPO (63 mg, 0.10 mmol) in dry methanol (10
5 mL), a solution of gadolinium nitrate pentahydrate (43 mg, 0.1 mmol) in dry methanol (10
6 mL) is added while stirring. The clear solution turns turbid after 2 drops of dry pyridine are
7 added. The mixture is refluxed overnight under nitrogen, during which time the complex
8 deposits as a white fluffy precipitate. It is filtered out, rinsed with cold methanol, and dried
9 to give the title complex (66 mg, 88%) as a white solid. MS (+FAB, NBA): 753.3
10 (MH⁺, 100%), shows an isotopic distribution typical for gadolinium compounds. Anal. for
11 GdC₂₇H₃₀N₇O₉ · 1.4 H₂O (779.05), Calcd. (found): C, 41.62 (41.70); H, 4.24 (4.26); N,
12 12.58 (12.28).

13 This complex is very stable in aqueous solution with a formation constant log β₁₁₀
14 of 20.3 and a pM value for Gd³⁺ of 19. This is substantially more stable than any of the
15 Gd³⁺ MRI agents in current clinical use.

16 Crystals of this compound suitable for x-ray diffraction are prepared by vapor
17 diffusion of ether into its wet DMF solution. Its chemical formula is GdC₂₉H₃₀N₇O₉ ·
18 2H₂O · C₃H₇NO. Its crystal structure is shown in Figure 2 and the crystallographic data and
19 parameters for this compound are shown in Table 2.

20 Solution of the structure indicates that the compound consists of molecules
21 containing one gadolinium (III) ion which coordinates with a hexadentate TREN-Me-3,2-
22 HOPO ligand and two water molecules, so that the square antiprism coordination
23 requirement of the gadolinium atom is satisfied by the oxygen atoms of three bidentate
24 hydroxypyridonate moieties and two water molecules. The structure reveals extensive
25 delocalization and a strong hydrogen bonding between the amide proton and its adjacent
26 HOPO oxygen donor, as shown in Formula 8. Because of the large number of coordinated

1 water molecules, this class of compounds is expected to show good nuclear magnetic
2 relaxation properties as need for magnetic resonance imaging.

3
4 Table 2.

5
6 Crystallographic Data and Parameters for $\text{GdO}_9\text{N}_7\text{C}_{27}\text{H}_{30}\cdot 2\text{H}_2\text{O}\cdot \text{C}_3\text{H}_7\text{NO}$
7

8		
9	Formula:	$\text{GdO}_9\text{N}_7\text{C}_{27}\text{H}_{30}\cdot 2\text{H}_2\text{O}\cdot \text{C}_3\text{H}_7\text{NO}$
10	Formula Weight (amu)	862.96
11	Temperature (° C)	-117
12	Crystal System	triclinic
13	Space Group (#)	$P\bar{1}$ (#2)
14	Cell Constants ^a	
15	a (Å)	10.791(3)
16	b (Å)	12.901(4)
17	c (Å)	13.566(4)
18	α (°)	85.42(2)
19	β (°)	67.38(2)
20	γ (°)	74.58(2)
21	Z	2
22	V(Å ³)	1680(1)
23	Abs. Coeff., μ_{calc} (cm ⁻¹)	20.54
24	d_{calc}	1.706
25	F(000)	874
26	Crystal dimensions (mm)	0.30 x 0.11 x 0.08 mm
27	Radiation	Mo-K α ($\lambda=0.71073$)
28	Diffractometer	Enraf-Nonius CAD-4
29	h, k, l range collected	0 \rightarrow 11, -13 \rightarrow +13, -14 \rightarrow +14
30	2 θ range	1.5 - 22.5
31	Scan Type	Omega-2Theta
32	Scan speed (θ , °/min.)	5.49°/min
33	Reflections collected	4377
34	Unique reflections:	4377
35	Reflections with ($F_o^2 > 3\sigma(F_o^2)$)	3576
36	Number of parameters	460
37	Data/parameter ratio	7.8
38	$R=[\sum \Delta F /\sum F_o]$	0.036
39	$R_w=[\sum w(\Delta F)^2/\sum wF_o^2]$	0.039
40	GOF	1.385
41	Final Diff. ρ_{max} (e ⁻ / Å ³)	+1.008 ^b
42		

43 ^aUnit cell parameters and their esd's were derived by a least-squares fitting of the setting angles of 24 reflections in
44 the range 23.24° \leq 2 θ \leq 24.56°.

45 ^bLocated near Gd.

EXAMPLE 21: *In Vivo* Test of Promoting Excretion of $^{238}\text{Pu}(\text{IV})$ in Mice by Injected Ligands

The novel chelating agents of the present invention were tested for their effectiveness in promoting excretion of $^{238}\text{Pu}(\text{IV})$ in mice by injected ligands as follows. Mice, in groups of five, each received an intravenous injection of 1850 Bq $^{238}\text{Pu}(\text{IV})$ in 0.2 mL of citrate buffer. One hour later, 30 $\mu\text{mol/kg}$ of ligand was injected intraperitoneally in 0.5 mL of saline. The mice were killed 24 hours after the Pu injection, frozen, and dissected after partial thawing. The ^{238}Pu in skeleton, soft tissues, and separated excreta was determined by counting the ^{234}U L x-rays. Results of removal of $^{238}\text{Pu}(\text{IV})$ from mice by injected ligands are summarized in Table 3, which also includes data for $\text{CaNa}_3\text{-DTPA}$ and other reference ligands and the Pu-injected controls. As illustrated by the data in Table 3, all the novel 3,2-HOPO chelating agents provide effective Pu removal, and the tetradentate ligands such as 5-LI-O-Me-3,2-HOPO, 5-LI-Me-3,2-HOPO and 4-LI-Me-3,2-HOPO are, surprisingly, as effective or more effective than the hexadentate and octadentate chelating agents. While in the case of multidentate 1,2-HOPO and catechoylamide chelating agents, octadentates are always better chelating agents than the correspond hexadentates and tetradentates.

Table 3.

Removal of $^{238}\text{Pu}(\text{IV})$ from Mice by Injected Ligands Composed of Me-3,2-HOPO

percent of injected $^{238}\text{Pu} \pm \text{SD}$ at 24 h ^{a,b}								
Ligand	no. of mice	tissues					excreta	
		skeleton	liver	soft tissue	kidneys	whole body	feces and GI contents	urine 0-24 h
Me-3,2-HOPO Ligands^c								
5-LI-O-Me-3,2-HOPO	5	11 \pm 1.6	2.1 \pm 0.3 ^d	1.6 \pm 0.2 ^d	0.2	15 \pm 2.1 ^d	61.7	23.5
5-LI-Me-3,2-HOPO	10	10 \pm 1.2	3.1 \pm 0.8 ^d	1.9 \pm 0.5	0.3	16 \pm 1.9 ^d	67.6	17.5

4-Li-Me-3,2-HOPO	10	11 ± 1.7	3.7 ± 1.5 ^d	1.9 ± 0.5	0.4	17 ± 2.4 ^d	63	19.4
TREN-Me-3,2-HOPO	15	10 ± 1.1	5.0 ± 2.2 ^d	2.5 ± 0.8	0.6	18 ± 2.7 ^d	43.3	37
H(2,2)-Me-3,2-HOPO	10	11 ± 1.7	3.8 ± 1.1 ^d	2.8 ± 1.6	1.3	19 ± 2.9 ^d	45.3	36
ME-Me-3,2-HOPO	5	12 ± 1.8	6.1 ± 4.9 ^d	3.0 ± 2.0	0.9	22 ± 8.5 ^d	70.1	33.5
6-Li-Me-3,2-HOPO	10	12 ± 1.8	6.5 ± 3.7 ^d	3.7 ± 1.8	0.5	23 ± 4.9 ^d	62.9	14.4
3-Li-Me-3,2-HOPO	10	14 ± 1.9	9.5 ± 4.9 ^d	2.6 ± 0.4	0.5	27 ± 5.2	41.6	32
H(3,2)-Me-3,2-HOPO	5	10 ± 2.0	14 ± 6.1	2.4 ± 0.3 ^d	1.2	28 ± 4.8	52.1	19.5
TREN-bis(Me-3,2-HOPO)-bis acetic acid	10	20 ± 1.7	6.6 ± 2.2 ^d	2.7 ± 0.8	0.5	30 ± 3.6	34.6	8.7
TRPN-Me-3,2-HOPO	5	14 ± 3.2	17 ± 5.0	2.0 ± 1.1	0.7	33 ± 5.3	11.5	55
H(4,2)-Me-3,2-HOPO	5	12 ± 2.9	29 ± 6.1	1.9 ± 1.0	1.8	46 ± 8.5	26.8	28
DFO-Me-3,2-HOPO ^e	10	17 ± 2.4	13 ± 3.5	19 ± 3.0	3.0	53 ± 3.4	26.4	21

Reference Ligands^{c,e}

DFO-(1,2-HOPO)	5	6.0 ± 0.5 ^d	5.1 ± 2.3 ^d	2.3 ± 0.5 ^d	0.1	13 ± 2.9 ^d	46.7	9.5
3,4,3-Li(1,2-HOPO)	5	7.5 ± 0.7 ^d	8.9 ± 1.7 ^d	1.6 ± 0.6 ^d	0.2	18 ± 1.7 ^d	57	23
CaNa ₃ -DTPA	15	12 ± 2.3	17 ± 4.0	3.5 ± 1.6	1.1	33 ± 6.6	5.1	61
3,4-Li(1,2-HOPO)	5	9.9 ± 3.6	18 ± 4.8	5.8 ± 1.3	0.6	34 ± 9.2	58	7.9
3-Li(1,2-HOPO)	5	17 ± 2.8	8.7 ± 1.2 ^d	11 ± 0.8	1.4	38 ± 4.4	53.3	8.7
DFO	10	20 ± 1.1	19 ± 1.3	4.5 ± 1.4	1.8	45 ± 2.5	15.1	38
ME-(1,2-HOPO)	5	17 ± 2.5	18 ± 6.3 ^d	10 ± 1.8	1.8	47 ± 9.4	43	9.6

Pu-Injected Controls (fed)

kill at 24 h	143	31 ± 7.4	50 ± 7.9 ^d	7.8 ± 2.1	1.8	91 ± 6.0	4.4	3.8
--------------	-----	----------	-----------------------	-----------	-----	----------	-----	-----

^a SD = $[\sum \text{dev}^2 / (n-1)]^{1/2}$. No SD is shown for kidneys or excreta, because samples for five-mouse groups were pooled for radioanalysis. Data for each mouse, expressed as % ID, were normalized to 100% material recovery; discrepancies are due to rounding.

^b Ligands were injected (30 $\mu\text{mol kg}^{-1}$, ip) at 1 h, and mice were killed at 24 h after iv injection of ²³⁸Pu(IV) citrate.

^c Skeleton, liver, and body Pu of ligand-treated groups are significantly less than 24 h Pu-injected controls (t test, $p \leq 0.01$).

^d Significantly different from mice given CaNa₃-DTPA (t test, $p \leq 0.01$).

^e Reported previously and shown here to facilitate comparisons.

EXAMPLE 22: *In Vivo* Test of Promoting Excretion of ²³⁸Pu(IV) in Mice by Orally Administered Ligands

The novel chelating agents of the present invention were tested for their effectiveness in promoting excretion of ²³⁸Pu(IV) by orally administration to mice as

follows. Mice in groups of five, each received an intravenous injection of 1850 Bq $^{238}\text{Pu}(\text{IV})$ in 0.2 mL of citrate buffer. Three minutes later, 30 mmol/kg of ligand was given by gavage in 0.5 ml of saline. The mice were killed 24 hours after the $^{238}\text{Pu}(\text{IV})$ injection, frozen, and dissected after partial thawing. The $^{238}\text{Pu}(\text{IV})$ in skeleton, soft tissues, and separated excreta was determined by counting the ^{234}U L x-rays. Results of removal of $^{238}\text{Pu}(\text{IV})$ from mice by orally administered ligands are summarized in Table 4, which also includes data for the reference ligands, and the Pu-injected controls. As illustrated by the data in Table 4, the octadentate and hexadentate chelating agents are superior by oral administration, and the hexadentate ligand TREN-Me-3,2-HOPO is the most effective both (by oral and injection) cases.

Table 4.

Removal of $^{238}\text{Pu}(\text{IV})$ from Mice by Orally
Administered Ligands Composed of Me-3,2-HOPO

percent of administered $^{238}\text{Pu} \pm \text{SD}$ at 24 h ^{a,b}								
Ligand	no. of mice	tissues					excreta	
		skeleton	liver	soft tissue	kidneys	whole body ^c	feces and GI contents	urine 0-24 h
Me-3,2-HOPO Ligands								
H(2,2)-Me-3,2-HOPO	15	11 \pm 4.6	7.6 \pm 6.5	4.0 \pm 2.1 ^c	0.4	23 \pm 11	37.9	39
TREN-Me-3,2-HOPO	10	13 \pm 5.5	8.5 \pm 4.7	1.9 \pm 1.2 ^c	0.7	25 \pm 12	34.1	42
H(3,2)-Me-3,2-HOPO	5	14 \pm 6.7	13 \pm 5.9	4.1 \pm 1.9	1.4	33 \pm 13	25.4	42
H(4,2)-Me-3,2-HOPO	5	15 \pm 6.2	19 \pm 4.9	1.8 \pm 0.8	1.3	37 \pm 10	10.1	52.4
5-LI-O-Me-3,2-HOPO	5	23 \pm 5.9	16 \pm 4.4	4.0 \pm 0.8 ^c	0.8	43 \pm 10	44.7	12.5
5-LI-Me-3,2-HOPO	5	23 \pm 11	24 \pm 5.3	4.4 \pm 2.0	0.8	53 \pm 17	27.1	20
4-LI-Me-3,2-HOPO	5	15 \pm 6.1	34 \pm 7.7	3.6 \pm 1.5	0.5	54 \pm 13	13.6	32.5
DFO-Me-3,2-HOPO	10	20 \pm 7.6	22 \pm 7.7	15 \pm 4.0	2.4	60 \pm 11	17.3	22.4
TRPN-Me-3,2-HOPO	5	28 \pm 8.0	28 \pm 3.1	4.3 \pm 1.7 ^c	0.7	60 \pm 11	35.5	5.4
3-LI-Me-3,2-HOPO	10	27 \pm 7.7 ^c	33 \pm 4.4	5.0 \pm 1.2	0.8	66 \pm 11	7.9	27
TREN-bis(Me-3,2-HOPO)bis acetic acid	10	28 \pm 5.2 ^c	38 \pm 2.7 ^d	4.1 \pm 0.7	0.6	71 \pm 5.6	10.0	19.1

6-Li-Me-3,2-HOPO	10	25 ± 3.1 ^c	44 ± 5.0	6.2 ± 1.1	1.3	76 ± 5.8 ^c	9.8	14.2
ME-Me-3,2-HOPO	5	34 ± 24.5	40 ± 1.8	7.5 ± 1.7	1.2	82 ± 3.9 ^c	6.7	12.4
<u>Reference Ligands^c</u>								
DFO-(1,2-HOPO)	5	12 ± 2.4	11 ± 4.9	1.3 ± 0.7	0.1	24 ± 7.7	51.4	25.7
3,4,3-Li(1,2-HOPO)	5	33 ± 5.0	22 ± 7.7 ^d	3.9 ± 0.8	0.2	60 ± 8.2	12.3	29
CaNa ₃ -DTPA	5	35 ± 2.7	45 ± 2.4 ^c	4.1 ± 0.7	1.1	85 ± 1.8	5.0	9.5
<u>Pu-Injected Controls (fed)</u>								
kill at 24 h	20	39 ± 7.2	43 ± 6.2 ^d	6.0 ± 1.5	1.6	90 ± 3.6	4.5	5.4

^a SD = $[\sum \text{dev}^2 (n-1)^{-1}]^{1/2}$. No SD is shown for kidneys or excreta, because samples for five-mouse groups were pooled for radioanalysis. Data for each mouse, expressed as % ID, were normalized to 100% material recovery; discrepancies are due to rounding.

^b Ligands were given (30 $\mu\text{mole kg}^{-1}$, by gavage) at 3 min, and mice were killed at 24 h after iv injection of ²³³Pu(IV) citrate.

^c Mean is significantly less than that of 24-h fasted Pu controls (t test, $p \leq 0.01$)

^d Mean is significantly less than that of mice gavaged with CaNa₃-DTPA (t test, $p \leq 0.01$)

EXAMPLE 23: *In Vivo* Test of Promoting Excretion of Am(III), Np(IV), and U(VI) in Mice by Injected TREN-Me-3,2-HOPO

One of the novel chelating agents of the present invention, TREN-Me-3,2-HOPO, was also tested for effectiveness in promoting excretion of ²⁴¹Am (III), ²³⁷Np (V), and ²³²U (VI) by injection into mice, as follows: Mice, in groups of five, each received an intravenous injection of (a) 1100 Bq of ²⁴¹Am(III) in 0.2 mL of citrate buffer, (b) 150 Bq of ²³²UO₂Cl₂ plus 3.6 mg of ²³⁵UO₂Cl₂ in 0.2 mL of saline, or (c) 200 Bq of ²³⁷NpO₂Cl (7.5 mg of ²³⁷NpO₂Cl) in 0.2 mL of saline. Three to five minutes later, 30 mmol/kg of TREN-Me-3,2-HOPO was injected intraperitoneally in 0.5 mL of saline. The mice were killed 24 hours after the actinide injection, frozen, and dissected after partial thawing. The skeleton, soft tissues, and separated excreta were radioanalyzed by counting the ²⁴¹Am gamma rays, or the alpha particles emitted by ²³⁷Np or ²³²U (and its ingrowing daughters). Removal of those actinides from mice by injected TREN-Me-3,2-HOPO is summarized in Table 5, which also includes data for mice similarly treated with CaNa₃-DTPA and for actinide-injected controls. As shown by the data in Table 5, TREN-Me-3,2-HOPO reduced the body content of all three actinides to a significantly greater degree than

CaNa₃-DTPA. Compared with controls, the Am content of all tissues was greatly reduced, the Np content of the soft tissues was significantly reduced, and more than one-half of the U burden in the kidneys was removed. The structure of Am(III)-TREN-Me-3,2-HOPO is considered to resemble that of the Gd(III) complexes (see example 20). Complexation of the fraction of Np(V) that is reduced *in vivo* to Np(IV) is considered to resemble that of Pu(IV). Complexation of U(VI) is considered to take place through binding to UO₂²⁺.

Table 5

Removal of ²⁴¹Am(III), ²³⁷Np(V), or ^{232,234,235}U(VI) from Mice by Injected TREN-Me-3,2-HOPO^a

Ligand	percent of injected actinide ± SD at 24 h ^{a,b,c}						
	tissues				excreta		
	skeleton	liver	soft tissue	kidneys	whole body	feces and GI contents	urine 0-24 h
<u>Am(III)</u>							
TREN-Me-3,2-HOPO	8.1 ± 1.6 ^d	1.0 ± 0.6 ^{d,e}	1.6 ± 0.6 ^d	0.2	11 ± 1.4 ^{d,e}	38	51
CaNa ₃ -DTPA	8.5 ± 0.9 ^d	13 ± 1.5 ^d	1.9 ± 0.3 ^d	0.4	24 ± 1.3 ^d	8.0	68
Am controls, kill 24h	27 ± 5.3	50 ± 5.3	5.7 ± 0.7	1.2	84 ± 3.7	2.6	14
<u>Np(V)</u>							
TREN-Me-3,2-HOPO	34 ± 4.5	3.8 ± 5.7 ^{d,e}	3.1 ± 1.1	1.0	42 ± 11 ^{d,e}	17	40
CaNa ₃ -DTPA	40 ± 4.4	14 ± 5.7	3.5 ± 0.9	1.3	58 ± 8.0	1.5	40
Np controls, kill 24 h	37 ± 5.1	1.4 ± 2.3	5.8 ± 2.3	1.7	59 ± 4.1	41 ^f	
<u>U(VI)</u>							
TREN-Me-3,2-HOPO	16 ± 2.4	0.6 ± 0.3	1.6 ± 0.3	9.4 ± 6.0 ^{d,e}	27 ± 8.5 ^{d,e}	23	70
CaNa ₃ -DTPA	19 ± 3.0	1.0 ^c	2.2 ± 0.1	17 ± 2.8	38 ± 0.7	62 ^f	
U controls, kill 24 h	17 ± 2.5	1.4 ^c	2.8 ± 0.5	19 ± 6.9	40 ± 7.8	60 ^f	

^a Ligands (30 mmol.kg⁻¹) i.p. at 3 to 5 min after actinide i.v.; kill at 24 h.

^b Groups of five mice except: TREN-Me-3,2-HOPO ip at 3 min after 24 h Am, 10; 24 h Am, Np, or U controls, 10. Results are expressed as percent of injected actinide (ID %) normalized to 100% material recovery, discrepancies are due to rounding.

^c Standard deviation. $SD = [\sum dev^2 / (n-1)]^{1/2}$. Kidneys of Am- and Np-injected mice, livers of some U-injected groups, and all excreta were pooled for each five-mouse group.

^d Significantly less actinide than appropriate controls (t test, $p \leq 0.01$).

^e Significantly improved actinide reduction than for mice given $CaNa_2-DTPA$ in same protocol.

^f Combined excreta.

EXAMPLE 24: *In Vivo* Toxicity Test of Injected Ligands in Mice

The test of acute toxicity of these novel ligands was carried out as follows. Groups of five mice were each given a single i.p. injection of 100 mmol/kg of ligand a day for 10 days or given two i.p. injection of 500 mmol/kg in 8 hours. The ligand was dissolved in 0.5 to 1.0 ml of saline at pH 7 to 8. After a period of observation, the mice were killed, selected tissues were removed and fixed for histopathological examination, and unusual findings at autopsy were recorded. Results of the initial test of toxicity of the ligands tested are summarized in Table 6. The highly effective ligands, such as TREN-Me-3,2-HOPO, 5-LI-Me-3,2-HOPO and 5-LI-O-Me-3,2-HOPO proved to be of low toxicity, even at the relatively high dosage of $2 \times 500 \mu\text{mol/kg}$ in 8 hours.

Table 6.

Initial Evaluation of Acute Toxicity in Mice of Ligands Composed of 1-Me-3,2-HOPO^a

protocol and ligand	study length (d) ^b	no. of mice	no. of survivors c	percent control mean \pm SD ^d		
				body weight	kidney weight	plasma urea N
I. 100 $\mu\text{mol} \cdot \text{kg}^{-1} \times 10$ daily						
TREN-Me-3,2-HOPO	11	5	5	102 \pm 1	-	112 \pm 10
TERN-Me-3,2-HOPO	21	5	5	106 \pm 4	-	120 \pm 9
H(2,2)-Me-3,2-HOPO	11	5	5	92 \pm 6	-	223 \pm 28
H(2,2)-Me-3,2-HOPO	21	5	5	87 \pm 9	-	225 \pm 188
5-LI-Me-3,2-HOPO	11	5	5	102 \pm 5	109 \pm 14	89 \pm 1
5-LI-Me-3,2-HOPO	21	5	5	102 \pm 5	100 \pm 4	101 \pm 2

5-LI-O-Me-3,2-HOPO	11	5	5	103 ± 5	100 ± 19	83 ± 5
5-LI-O-Me-3,2-HOPO	21	5	5	101 ± 5	111 ± 5	86 ± 18
IA. 100 µmol·kg ⁻¹ x 2 daily						
3-LI-Me-3,2-HOPO	6	10	0	<u>89 ± 4</u>	<u>222 ± 29</u>	<u>>1800</u>
6-LI-Me-3,2-HOPO	3	5	5	<u>83 ± 3</u>	<u>132 ± 11</u>	<u>343 ± 140</u>
6-LI-Me-3,2-HOPO	11	5	3	101 ± 5	112 ± 13	92 ± 6
IB. 100 µmol·kg ⁻¹						
4-LI-(Me-3,2-HOPO	5	3	0	85 ± 8	190 ± 63	>2000
II. 500 µmol·kg ⁻¹ x 2 in 8 h						
TREN-(Me-3,2-HOPO	8	19 ^c	19	101 ± 4	-	119 ± 15
H(2,2)-(Me-3,2-HOPO)	8	10	3	<u>94 ± 6</u>	-	<u>169 ± 10</u>
5-LI-Me-3,2-HOPO	11	5	5	99 ± 3	109 ± 9	98 ± 18
5-LI-O-Me-3,2-HOPO	11	10	10	100 ± 2	108 ± 10	<u>77 ± 10</u>

^a Control data: Body weight ratio, (W(t)/W(o)) 8 to 11 d, 1.01 ± 0.03 (15); 21 d, 1.06 ± 0.06 (10).
Kidney weight (g), 2 x left kidney, 0.44 ± 0.04 (25). Plasma urea N (mg dL⁻¹) (15 groups of five) range 11.4 ± 1.2 to 22.2 ± 2.5, median 20.2 ± 2.3, grand mean 15 groups 18.5 ± 3.2.

^b Days after first ligand injection

^c Number of survivors and of autopsied mice contributing numerical data, with two exceptions. In the case of 3-LI-


Me-3,2-HOPO data are shown for two moribund mice autopsied on d 3; all mice were dead by d 3. In all cases mice found dead were not autopsied.

^d Underlined means significantly different from control means, t test, $p < 0.01$.

^e Two replicate 10-mouse groups, one mouse lost in an injection accident.

CLAIMS




1. A hydroxypyridinone chelating agent selected from the group consisting of:



wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

2. A hydroxypyridinone chelating agent according to claim 1, wherein said linking group is a molecular backbone linking group; and said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.


3. A hydroxypyridinone chelating agent according to claim 2, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:



1
2 or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo
3 groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said
4 molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁-
5 ₈ aliphatic hydrocarbon groups, aryl groups and C₁-₈ aliphatic hydrocarbon groups
6 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected
7 from hydrogen, C₁-₄ aliphatic hydrocarbon groups, and C₁-₄ aliphatic hydrocarbon groups
8 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
9 group.

10
11 4. A hydroxypyridinone chelating agent according to claim 3, wherein said molecular
12 backbone linking group additionally bears at least one chelating functional unit selected
13 from the group consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides,
14 and hydroxamic acids.




15
16 5. A hydroxypyridinone chelating agent according to claim 3, wherein all of said chelating
17 functional units are:
18



- 1 6. A hydroxypyridinone chelating agent according to claim 1, wherein said backbone
2 linking group is a polymeric backbone linking group.

3

- 4 7. A hydroxypyridinone chelating agent according to claim 6, wherein said polymeric backbone
5 linking group additionally bears a combination of at least one type of chelating functional unit
6 selected from the group consisting of:



7

- 8 or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo
9 groups of a hydroxypyridinone ring; an amide free valency is a point of attachment to said
10 polymeric backbone linking group; R' is selected from the group consisting of hydrogen, C₁-
11 8 aliphatic hydrocarbon groups, aryl groups and C₁-8 aliphatic hydrocarbon groups
12 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected
13 from hydrogen, C₁-4 aliphatic hydrocarbon groups, and C₁-4 aliphatic hydrocarbon groups
14 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
15 group.

16

- 17 8. A chelating agent according to claim 7, wherein said polymeric backbone linking group
18 additionally bears chelating functional units selected from the group consisting of: amino
19 acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

20

- 21 9. The chelating agent 5-LI-O-Me-3,2-HOPO.


22

- 23 10. The chelating agent 5-LI-Me-3,2-HOPO.

11. The chelating agent TREN-Me-3,2-HOPO.

12. The chelating agent H(2,2)-Me-3,2-HOPO.

13. A pharmaceutical composition comprising the chelating agent selected from the group consisting of:






wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, together with a physiologically acceptable diluent or carrier.

14. A pharmaceutical composition according to claim 13 which further comprises a solid carrier and is in a form suitable for oral administration.

15. A pharmaceutical composition according to claim 14, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.


- 1 16. A pharmaceutical composition according to claim 15, wherein said molecular backbone
 2 linking group additionally bears at least one chelating functional unit selected from the group
 3 consisting of:



- 4
 5 or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo
 6 groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said
 7 molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁-
 8 aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups
 9 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected
 10 from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups
 11 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
 12 group.

- 13
 14 17. A pharmaceutical composition according to claim 16, wherein said molecular backbone
 15 linking group additionally bears chelating functional units selected from the group
 16 consisting of: amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic
 17 acids.


- 18
 19 18. A method of removing actinides and iron from a mammalian body which comprises
 20 administration of a physiologically acceptable amount of a chelating agent selected from the
 21 group consisting of:
 22



wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group.

19. A method according to claim 18, wherein said molecular backbone linking group is of linear, branched linear, multipodal or macrocyclic topology.

20. A method according to claim 19, wherein said molecular backbone linking group additionally bears at least one chelating functional unit selected from the group consisting of:




or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said

1 molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁-
 2 8 aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups
 3 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected
 4 from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups
 5 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
 6 group.

7
 8 21. A method according to claim 20, wherein said molecular backbone linking group
 9 additionally bears chelating functional units selected from the group consisting of: amino
 10 acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

11
 12 22. A method of removing actinides and iron from a mammalian body which comprises
 13 administration of a pharmaceutical composition comprising the chelating agent selected from the
 14 group consisting of:
 15




16
 17 wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone
 18 ring; R is a molecular backbone linking group; R' is selected from the group consisting of
 19 hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups
 20 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected from
 21 hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups substituted
 22 by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl group, together
 23 with a physiologically acceptable diluent or carrier.

- 1 23. A method of removing actinides and iron from a mammalian body which comprises
 2 administration of a pharmaceutical composition according to claim 22 which further comprises a
 3 solid carrier and is in a form suitable for oral administration.

- 4
 5 24. A method according to claim 23, wherein said molecular backbone linking group is of
 6 linear, branched linear, multipodal or macrocyclic topology.


- 7
 8 25. A method according to claim 24, wherein said molecular backbone linking group
 9 additionally bears at least one chelating functional unit selected from the group consisting of:



- 10
 11 or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo
 12 groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said
 13 molecular backbone linking group; R' is selected from the group consisting of hydrogen, C_{1-8}
 14 aliphatic hydrocarbon groups, aryl groups and C_{1-8} aliphatic hydrocarbon groups
 15 substituted by amino, carboxy, or hydroxy groups; and R_1 and R_2 are separately selected
 16 from hydrogen, C_{1-4} aliphatic hydrocarbon groups, and C_{1-4} aliphatic hydrocarbon groups
 17 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
 18 group.

- 19
 20 26. A method according to claim 25, wherein said molecular backbone linking group
 21 additionally bears chelating functional units selected from the group consisting of: amino
 22 acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.


- 1 27. MRI diagnosis agents containing complexes of chelating agents selected from the group
 2 consisting of:



- 3
 4 wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a
 5 hydroxypyridinone ring; R is a molecular backbone linking group; R' is selected from the
 6 group consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈
 7 aliphatic hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and
 8 R₂ are separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄
 9 aliphatic hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono,
 10 acrylamido group or an aryl group.

- 11
 12 28. MRI diagnosis agents according to claim 27, wherein said molecular backbone linking
 13 group is of linear, branched linear, multipodal or macrocyclic topology.

- 14
 15 29. MRI diagnosis agents according to claim 28, wherein said molecular backbone linking group
 16 additionally bears at least one chelating functional unit selected from the group consisting of:



18

1 or mixtures thereof, wherein a substituted carbamoyl group is ortho to hydroxy or oxo
2 groups of a hydroxypyridinone ring; an amide free valency is the point of attachment to said
3 molecular backbone linking group; R' is selected from the group consisting of hydrogen, C₁-
4 ₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic hydrocarbon groups
5 substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are separately selected
6 from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic hydrocarbon groups
7 substituted by a single halide, hydroxy, carboxy, phosphono, acrylamido group or an aryl
8 group.


9
10 30. MRI diagnosis agents according to claim 29, wherein said molecular backbone linking
11 group additionally bears chelating functional units selected from the group consisting of:
12 amino acetic acid, catechols, 2,3-dihydroxyterephthalamides, and hydroxamic acids.

13
14 31. An improved process of synthesizing 3-hydroxy-1-alkyl-2(1H)-pyridinone comprising
15 the steps:

- 16 (1) heating a mixture of 2,3-dihydroxypyridine and iodoalkane in a closed,
17 explosion resistant, sealable container to create an oil;
18 (2) mixing said oil with inorganic sulfite salt and water to create a solution;
19 (3) neutralizing said solution,
20 (4) filtering said solution;
21 (4) extracting said solution to create an extract;
22 (5) purifying said extract with a flash silica gel plug to create a purified extract; and
23 (6) evaporating said purified extract.

24
25 32. A process of synthesizing 4-carboxy-3-hydroxy-2(1H)-pyridinones of the following
26 formula,


27



comprising the steps:

- (1) mixing 3-hydroxy-2(1H)-pyridinones and anhydrous potassium carbonate in about 1:3 to 1:5 mol ratio to create a mixture;
- (2) placing said mixture in a closed, explosion resistant, sealable container and filling with dry carbon dioxide gas to about 600-900 psi;
- (3) heating said mixture to about 170-200° C for about 24-72 hours;
- (4) cooling said mixture to create a solid; and
- (5) dissolving said solid in water to create a solution;
- (6) acidifying said solution with mineral acid to create an acidified solution; and
- (7) filtering said acidified solution to create said 4-carboxy-3-hydroxy-2(1H)-pyridinones.


33. A process of synthesizing hydroxypyridinone chelating agents selected from the group consisting of:



wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group

1 consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic
 2 hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are
 3 separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic
 4 hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono,
 5 acrylamido group or an aryl group, wherein said molecular backbone linking group is of
 6 linear, branched linear, multipodal or macrocyclic topology and said molecular backbone
 7 linking group bears a combination of said chelating functional units, comprising the steps:

8 (1) reacting an acid selected from the group consisting of:




11 with a hydroxy group protecting agent to create a protected HOPO carboxylic acid;

12 (2) converting said protected HOPO carboxylic acid to an activated species, which
 13 is selected from the group consisting of an activated ester, an activated amide, or an acid
 14 chloride;

15 (3) reacting said activated species with a backbone amine to create a hydroxy-
 16 protected chelating agent; and

17 (4) deprotecting said hydroxy-protected chelating agent to generate said
 18 hydroxypyridinone chelating agent.

19
 20 34. A process of synthesizing bidentate and multidentate hydroxypyridinone chelating agents
 21 selected from the group consisting of:
 22




1

2

3 wherein a substituted carbamoyl group is ortho to hydroxy or oxo groups of a
 4 hydroxypyridinone ring; R is a backbone linking group; R' is selected from the group
 5 consisting of hydrogen, C₁₋₈ aliphatic hydrocarbon groups, aryl groups and C₁₋₈ aliphatic
 6 hydrocarbon groups substituted by amino, carboxy, or hydroxy groups; and R₁ and R₂ are
 7 separately selected from hydrogen, C₁₋₄ aliphatic hydrocarbon groups, and C₁₋₄ aliphatic
 8 hydrocarbon groups substituted by a single halide, hydroxy, carboxy, phosphono,
 9 acrylamido group or an aryl group, comprising the steps:

10 (1) mixing an acid selected from the group consisting of:

11



12

13

14 with a hydroxy group protecting agent in 1:1.2 mol ratio and excess anhydrous potassium
 15 carbonate in a suitable solvent to create a first mixture;

16 (2) heating said first mixture at about 65-80° C under N₂ in darkness for about 16
 17 hours,


18 (3) filtering said first mixture to create a filtrate;

19 (4) evaporating said filtrate to create an oil;

- 1 (5) mixing said oil with a solution of mineral base for about 4-8 hours to create a
- 2 second mixture;
- 3 (6) evaporating said second mixture to dryness to create a solid;
- 4 (7) dissolving said solid in water to create a solution;
- 5 (8) acidifying said solution with mineral acid to precipitate a solid acid;
- 6 (9) converting said solid acid to activated amide, acid chloride or activated ester;
- 7 (10) mixing said activated amide, acid chloride or activated ester with a proper
- 8 backbone amine in a proper solvent for about 4-8 hours to create a raw protected ligand;
- 9 (11) purifying said raw protected ligand to create a protected ligand;
- 10 (12) deprotecting said protected ligand with a suitable acid or catalytic
- 11 hydrogenation and filtration to create a filtrate;
- 12 (13) evaporating said filtrate to create a residue;
- 13 (14) recrystallizing said residue with a suitable solvent to obtain a pure
- 14 hydroxypyridinone chelating agent.

15

1/2

**FIG. 1.**

2/2




FIG. 2.

INTERNATIONAL SEARCH REPORT

Intern. al Application No
PCT/US 95/07766

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D213/81 C07D213/89 C07C233/77 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US,A,4 698 431 (RAYMOND KENNETH N ET AL) 6 October 1987 cited in the application see column 3, line 35 - column 6, line 40; examples 2-12 ---	1-34
A	US,A,4 666 927 (HIDER ROBERT C ET AL) 19 May 1987 cited in the application see the whole document --- -/--	1-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

27 December 1995

Date of mailing of the international search report

- 4. 01. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

Intern. Patent Application No

PCT/US 95/07766

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 14, 7 July 1995 WASHINGTON US, pages 2606-2614, J. XU ET AL. 'Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxy-1-methyl-2(1H)-pyrid inone ligands for in vivo plutonium(IV) chelation.' see the whole document ---	1-34
X	CHEMICAL ABSTRACTS, vol. 122, no. 1, 2 January 1995 Columbus, Ohio, US; abstract no. 4449p, P. DURBIN ET AL. 'In vivo chelation of Am(III), Pu(IV), Np(V) and U(VI) in mice by TREN-(Me-3,2-HOPO).' page 517; see abstract; CAS RN 159356-07-7 & RADIATION PROTECTION DOSIMETRY., vol. 53, no. 1-4, 1994 ASHFORD, ENGL., pages 305-309, ---	1-34
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 4, 1993 WASHINGTON US, pages 504-509, L.C. UHLIR ET AL. 'Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands.' see compound 3; Figure 1 see table I ---	1-30
X	CHEMICAL ABSTRACTS, vol. 105, no. 25, 22 December 1986 Columbus, Ohio, US; abstract no. 221872z, R.J. BERGERON ET AL. 'Catecholamide chelators for actinide environmental and human decontamination.' page 374; see abstract & CHEMICAL SEPARATIONS, DEVELOPED FROM SELECTED PAPERS PRESENTED AT THE INTERNATIONAL CONFERENCE ON SEPARATIONS SCIENCE AND TECHNOLOGY, 1ST, NEW YORK, 1986, vol. 2, 1986 DENVER, pages 123-127, ---	1,13,18, 22,27

-/--

INTERNATIONAL SEARCH REPORT

Intern Application No
PCT/US 95/07766

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 101, no. 15, 8 October 1984 Columbus, Ohio, US; abstract no. 125980e, P.W. DURBIN ET AL. 'Specific sequestering agents for the actinides: Enhancement of plutonium-238 elimination from the mice by poly(catechoylamide) ligands.' page 328; see CAS RN 69146-59-4 see abstract & RADIATION RESEARCH, vol. 99, no. 1, 1984 NEW YORK, pages 85-105, ---	1,13,18, 22,27
X	CHEMICAL ABSTRACTS, vol. 92, no. 13, 31 March 1980 Columbus, Ohio, US; abstract no. 106582f, R.A. BULMAN ET AL. 'An examination of some complexing agents for ability to remove intracellularly deposited plutonium.' page 286; see CAS RN 16414-49-6 see abstract & HEALTH PHYSICS, vol. 37, no. 6, 1979 NEW YORK, pages 729-934, ---	1,13,18, 22,27
X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 6, 1990 WASHINGTON US, pages 1749-1755, M. STREATER ET AL. 'Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, Iron(III)-chelating properties, and biological activity.' see Scheme I -----	31

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 07766

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 18-26 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The subject matter of the present claims 1, 13, 18, 22 and 27 is so broad that a complete search is not possible on economic grounds (PCT Search Guidelines III, 3.5 and 3.7). Therefore the search has been based on the examples and the claims as indicated.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/US 95/07766

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4698431	06-10-87	NONE	
US-A-4666927	19-05-87	DE-D- 3486255	20-01-94
		DE-T- 3486255	24-03-94
		EP-A, B 0138421	24-04-85
		EP-A- 0357150	07-03-90
		GB-A, B 2146989	01-05-85
		JP-C- 1880001	21-10-94
		JP-B- 6002739	12-01-94
		JP-A- 60094965	28-05-85
		JP-A- 2191254	27-07-90
		JP-B- 6002740	12-01-94
		US-A- 5104865	14-04-92
		US-A- 4863913	05-09-89
		US-A- 4912118	27-03-90

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.